Botulinum toxin type A versus botulinum toxin type B for cervical dystonia by Duarte, GS et al.
Cochrane Database of Systematic Reviews
Botulinum toxin type A versus botulinum toxin type B for
cervical dystonia (Review)
Duarte GS, Castelão M, Rodrigues FB, Marques RE, Ferreira J, Sampaio C, Moore AP, Costa J
Duarte GS, CastelãoM, Rodrigues FB, Marques RE, Ferreira J, Sampaio C, Moore AP, Costa J.
Botulinum toxin type A versus botulinum toxin type B for cervical dystonia.
Cochrane Database of Systematic Reviews 2016, Issue 10. Art. No.: CD004314.
DOI: 10.1002/14651858.CD004314.pub3.
www.cochranelibrary.com
Botulinum toxin type A versus botulinum toxin type B for cervical dystonia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
7BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
15RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
21DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
23AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
23ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
24REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
28CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
38DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 1 Overall cervical dystonia
improvement as assessed with validated scales: change from baseline to week 4. . . . . . . . . . . . 39
Analysis 1.2. Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 2 Cervical dystonia associated
severity: change from baseline to week 2-4 as assessed with validated scales. . . . . . . . . . . . . . 40
Analysis 1.3. Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 3 Cervical dystonia associated
disability: change from baseline to week 2-4 as assessed with validated scales. . . . . . . . . . . . . 41
Analysis 1.4. Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 4 Proportion of participants
with adverse events. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
Analysis 1.5. Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 5 Subjective change as
assessed by the patient at week 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
Analysis 1.6. Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 6 Subjective change as
assessed by clinician at week 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
Analysis 1.7. Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 7 Cervical dystonia associated
pain: change from baseline to week 2-4 as assessed with validated scales. . . . . . . . . . . . . . . 43
Analysis 1.8. Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 8 Adverse event: sore
throat/dry mouth. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
Analysis 1.9. Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 9 Adverse event: dysphagia. 45
Analysis 1.10. Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 10 Adverse event: injection
site pain. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
46ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
47APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
49WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
49HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
49CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
50DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
50SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
51DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
51INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iBotulinum toxin type A versus botulinum toxin type B for cervical dystonia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Botulinum toxin type A versus botulinum toxin type B for
cervical dystonia
Gonçalo S Duarte1,2a , Mafalda Castelão1,2b, Filipe B Rodrigues1 ,2c, Raquel E Marques1 ,2d , Joaquim Ferreira1,2, Cristina Sampaio
3, Austen P Moore4, João Costa1 ,2
1Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina de Lisboa, Lisboa, Portugal. 2Clinical Pharmacology Unit,
Instituto de Medicina Molecular, Lisboa, Portugal. 3CHDI Foundation, Princeton, NJ, USA. 4The Walton Centre NHS Foundation
Trust, Liverpool, UK
aThese authors contributed equally to this work. bThese authors contributed equally to this work. cThese authors contributed equally
to this work. dThese authors contributed equally to this work
Contact address: João Costa, Clinical Pharmacology Unit, Instituto de Medicina Molecular, Av. Prof. Egas Moniz, Lisboa, 1649-028,
Portugal. jncosta@medicina.ulisboa.pt.
Editorial group: Cochrane Movement Disorders Group.
Publication status and date: New search for studies and content updated (conclusions changed), published in Issue 10, 2016.
Review content assessed as up-to-date: 26 October 2015.
Citation: Duarte GS, Castelão M, Rodrigues FB, Marques RE, Ferreira J, Sampaio C, Moore AP, Costa J. Botulinum toxin type A
versus botulinum toxin type B for cervical dystonia. Cochrane Database of Systematic Reviews 2016, Issue 10. Art. No.: CD004314.
DOI: 10.1002/14651858.CD004314.pub3.
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
This is an update of a Cochrane review first published in 2003. Cervical dystonia is the most common form of focal dystonia and is a
disabling disorder characterised by painful involuntary head posturing. There are two available formulations of botulinum toxin, with
botulinum toxin type A (BtA) usually considered the first line therapy for this condition. Botulinum toxin type B (BtB) is an alternative
option, with no compelling theoretical reason why it might not be as- or even more effective - than BtA.
Objectives
To compare the efficacy, safety and tolerability of botulinum toxin type A (BtA) versus botulinum toxin type B (BtB) in people with
cervical dystonia.
Search methods
To identify studies for this review we searched the Cochrane Movement Disorders Group Trials Register, the Cochrane Central Register
of Controlled Trials (CENTRAL), MEDLINE, Embase, reference lists of articles and conference proceedings. All elements of the
search, with no language restrictions, were last run in October 2016.
Selection criteria
Double-blind, parallel, randomised, placebo-controlled trials (RCTs) comparing BtA versus BtB in adults with cervical dystonia.
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Data collection and analysis
Two independent authors assessed records, selected included studies, extracted data using a paper pro forma, and evaluated the risk of
bias. We resolved disagreements by consensus or by consulting a third author. We performed meta-analyses using the random-effects
model, for the comparison BtA versus BtB to estimate pooled effects and corresponding 95% confidence intervals (95% CI). No
prespecified subgroup analyses were carried out. The primary efficacy outcome was improvement on any validated symptomatic rating
scale, and the primary safety outcome was the proportion of participants with adverse events.
Main results
We included three RCTs, all new to this update, of very low to low methodological quality, with a total of 270 participants.
Two studies exclusively enrolled participants with a known positive response to BtA treatment. This raises concerns of population
enrichment, with a higher probability of benefit from BtA treatment. None of the trials were free of for-profit bias, nor did they
provide information regarding registered study protocols. All trials evaluated the effect of a single Bt treatment session, and not repeated
treatment sessions, using doses from 100 U to 250 U of BtA (all onabotulinumtoxinA, or Botox, formulations) and 5000 U to 10,000
U of BtB (rimabotulinumtoxinB, or Myobloc/Neurobloc).
We found no difference between the two types of botulinum toxin in terms of overall efficacy, with a mean difference of -1.44 (95%
CI -3.58 to 0.70) points lower on the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) for BtB-treated participants,
measured at two to four weeks after injection. The proportion of participants with adverse events was also not different between BtA
and BtB (BtB versus BtA risk ratio (RR) 1.40; 95% CI 1.00 to 1.96). However, when compared to BtA, treatment with BtB was
associated with an increased risk of one adverse events of special interest, namely treatment-related sore throat/dry mouth (BtB versus
BtA RR of 4.39; 95% CI 2.43 to 7.91). Treatment-related dysphagia (swallowing difficulties) was not different between BtA and BtB
(RR 2.89; 95% CI 0.80 to 10.41). The two types of botulinum toxin were otherwise clinically non-distinguishable in all the remaining
outcomes.
Authors’ conclusions
The previous version of this review did not include any trials, since these were still ongoing at the time. Therefore, with this update
we are able to change the conclusions of this review. There is low quality evidence that a single treatment session of BtA (specifically
onabotulinumtoxinA) and a single treatment session of BtB (rimabotulinumtoxinB) are equally effective and safe in the treatment
of adults with certain types of cervical dystonia. Treatment with BtB appears to present an increased risk of sore throat/dry mouth,
compared to BtA. Overall, there is no clinical evidence from these single-treatment trials to support or contest the preferential use of
one form of botulinum toxin over the other.
P L A I N L A N G U A G E S U M M A R Y
A comparison of botulinum toxin type A versus botulinum toxin type B for involuntary positioning of the head, or cervical
dystonia
The review question
We reviewed the evidence about the effect of botulinum toxin type A (BtA) compared to botulinum toxin type B (BtB) in people
with involuntary positioning of the head, or cervical dystonia. This is an update of a previous Cochrane Review and we assessed the
effectiveness (reduction in severity, disability and pain) and safety of BtA versus BtB in cervical dystonia.
Background
Cervical dystonia, also called spasmodic torticollis, is a disease that causes undesired, uncontrollable, often painful, abnormal placement
of the head. It is a relatively uncommon condition (affecting 57 to 280 people per million) that can be very disabling and can affect
a person’s quality of life negatively. In most cases the cause is unknown and no cure exists. Since cervical dystonia is normally a long-
term disease it requires long-term treatment.
Botulinum toxin (Bt) is a powerful, natural chemical that can cause severe paralysis (an inability to move in the part of the body
where it is applied) in animals and humans. It can also be used to treat many conditions, in particular those with involuntary muscle
contractions, such as cervical dystonia. Bt is delivered by injections into the muscles that contract to produce the disease. There are
different types of Bt, not all are available for treating health conditions. BtA is typically the first-used treatment in cervical dystonia,
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but botulinum toxin type B (BtB) is an alternative option. The relative strength of each Bt formulation is variable, and the cost for 200
units varies from GBP 198 to GBP 308.
Study characteristics
We performed a rigorous search of the medical literature in October 2016 and found three studies that compared a single treatment
session of BtA with BtB. These studies included a total of 270 participants, with on average a moderate disease impairment. The
participants remained in the studies for a short period of time - between 16 and 20 weeks after the treatment. The average age of people
in the studies was 53.3 years, and they had had cervical dystonia for an average of 6.6 to 7.9 years before taking part in the trials. Most,
63.3%, of the people in the studies were women. All three of the studies were funded by drug manufacturers with possible interests in
the results of the studies.
Key results
The results show little or no difference between BtA and BtB in the main measures of overall improvement and safety, including the
total number of adverse (unwanted or harmful) events. There was also little or no difference between BtA and BtB in the self-evaluations
reported by the study participants. Based on the results we would expect that, out of 1000 people with cervical dystonia treated with
BtB, there would be 362 more people who experience dry mouth/sore throat compared to 1000 people treated with BtA. The studies
which looked at the duration of effect showed little or no difference between BtA and BtB. None of the studies examined the impact
of either Bt on quality of life.
Quality of the evidence
All of the studies included participants that were different to the average person who suffers from cervical dystonia. To be included
participants had to have a history of successful treatment with Bt. People with certain types of cervical dystonia, in particular the forms
that make the head turn backward or forward, were not allowed to participate in the studies.
Not enough participants were included across the studies for us to be completely confident in the results for the total number of adverse
events, the self-reported evaluations by participants or the pain assessment.
The quality of the evidence for overall improvement and total number of adverse events was low. The quality of the evidence for more
sore throat/dry mouth in people receiving BtB is moderate. The quality of the evidence where participants gave their self-assessments
is low.
No definite conclusions can be drawn regarding overall safety and long-term utility of BtA compared to BtB in cervical dystonia.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Botulinum toxin type A compared to botulinum toxin type B for adults with cervical dystonia
Patient or population: adults with cervical dystonia
Settings: hospital-based, movement disorders clinics
Intervention: botulinum toxin type A
Comparison: botulinum toxin type B
Outcomes Relative effect
(95% CI)
Anticipated absolute effects∗ (95% CI) Quality of the evidence
(GRADE)
What happens
With botulinum toxin
type A
With botulinum toxin
type B
Difference
Overall cervical dysto-
nia
improvement: change
f rom baseline to week 4
assessed with TWSTRS
total score
Scale (range, 0 to 85;
more is worst)
of part icipants: 231
(2 RCTs)
- 9.1 TWSTRS units de-
crease
10.5 TWSTRS units de-
crease
The mean change f rom
baseline was 1.44 TW-
STRS units higher (0.
7 lower to 3.58 higher)
in the BtB group com-
pared to the BtA group
⊕⊕©©
LOW 1,2
Due to study lim itat ions
and imprecision
There may be lit t le or no
dif ference in the over-
all cervical dystonia im-
provement
Participants with ad-
verse events
of part icipants: 111
(1 RCT)
RR 1.40
(1.00 to 1.96)
47.3% 66.2% 18.9% more adverse
events
(0 fewer to 45.4 more)
⊕⊕©©
LOW 3
Due to imprecision
There may be lit t le or
no dif ference in the risk
of adverse events
Subjective change as
assessed by the patient
at week 4
assessed with: PGA
Scale (range, -4 to 4;
more is worst)
of part icipants: 138
- 1.6 PGA units decrease 1.4 PGA units decrease The mean subject ive
change in the BtB group
was 0.2 PGA units lower
(0.17 lower to 0.57
higher) compared to the
BtA group
⊕⊕©©
LOW 2,4
Due to study lim itat ions
and imprecision
There may be lit t le or no
dif ference in subject ive
assessment
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(1 RCT)
Cervical dystonia as-
sociated pain: change
from baseline to week
2-4
assessed with TWSTRS
pain sub-scale
Scale (range, 0 to 20;
more is worst)
of part icipants: 251
(3 RCTs)
- 2.63 TWSTRS units de-
crease
3.45 TWSTRS units de-
crease
The mean change was
0.83 TWSTRS units
higher (1.75 lower to 0.
09 higher) in the BtB
group compared to the
BtA group
⊕⊕©©
LOW 2,4
Due to study lim itat ions
and imprecision
There may be lit t le or
no dif ference in the risk
of cervical dystonia-as-
sociated pain
Adverse events: sore
throat/ dry mouth
of part icipants: 212
(2 RCTs)
RR 4.39
(2.43 to 7.91)
10.5% 46.7%
(25.5 to 82.9)
35.5% more
(15 more to 72.4 more)
⊕⊕⊕©
M ODERATE2,4
Due to study lim itat ions
and imprecision
BtB treatment probably
increases the risk of
sore throat/ dry mouth
Adverse events: dys-
phagia
of part icipants: 249
(3 RCTs)
RR 2.89
(0.80 to 10.41)
10.2% 29.4%
(8.1 to 100.0)
19.2% more
(2 fewer to 95.6 more)
⊕⊕©©
LOW 2,4,5
Due to study lim ita-
t ions, imprecision, and
inconsistency
There may be lit t le or
no dif ference in the risk
of dysphagia
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
BtA: botulinum toxin type A; BtB: botulinum toxin type B; CI: conf idence interval;PGA: Patient Global Assessment; RCT: randomised controlled trial; RR: risk rat io; TWSTRS:
Toronto Western Spasmodic Tort icollis Rat ing Scale
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
M oderate quality: we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: we have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Serious imprecision: 95% CI includes both appreciable benef it and no ef fect. This means that we cannot conclusively state
the equivalence of these two formulat ions.5
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2 Serious study lim itat ions: the lim itat ions in the studies assessing this outcome are serious and af fect our conf idence in the
accuracy of the ef fect est imate.
3 Very serious imprecision: the total number of part icipants included was less than the number generated by a convent ional
sample size calculat ion for a single adequately powered equivalence trial. 95% CI includes both appreciable benef it and harm
meaning that we cannot conclusively state the equivalence of these two formulat ions.
4 Serious imprecision: the total number of part icipants included was less than the number generated by a convent ional sample
size calculat ion for a single adequately powered equivalence trial.
5 Serious inconsistency: high degree of heterogeneity expressed by I2 and low overlap of 95% CI.
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B A C K G R O U N D
This review is an update of a previously published review in the
Cochrane Database of Systematic Reviews 2003, Issue 3 (Costa
2003), evaluating the efficacy and safety of botulinum toxin type
A (BtA) versus botulinum toxin type B (BtB) in the treatment of
cervical dystonia.
Description of the condition
See Table 1 for glossary of terms.
Dystonia is the third most common movement disorder, after
Parkinson’s disease and essential tremor, with an overall prevalence
of 164 permillion (Steeves 2012).Dystonia syndromes are a group
of disabling, painful disorders characterised by involuntary sus-
tained or intermittent muscle contractions that cause abnormal,
often repetitive, movements or postures of the face, neck, trunk
or limbs (Albanese 2013). Dystonic movements are typically pat-
terned or twisting, and are often initiated or worsened by volun-
tary action (Albanese 2013). These neurological disorders can be
classified on the basis of topographic distribution, including fo-
cal dystonia (one body region, e.g. cervical dystonia (involuntary
movements of head and neck) and blepharospasm (involuntary
closure of the eyes)), segmental dystonia (two or more adjacent
regions), multifocal dystonia (two or more nonadjacent regions),
hemidystonia (ipsilateral regions (same side of the body)) and gen-
eralised dystonia (trunk and two or more other regions) (Albanese
2013; Tarsy 2006).
Focal dystonia is a highly disabling movement disorder, with se-
rious functional and social impairment. Close to half of the dys-
tonia patient population quits work by the age of forty or retires
early due to the condition, and 10 years later, only 25% of people
are working compared to 62% of the general population (Zoons
2012). Moreover, health-related quality of life is significantly di-
minished, mainly due to depression and anxiety, with scores com-
parable to people with multiple sclerosis, Parkinson’s disease or
stroke (Zoons 2012).
Cervical dystonia, also called spasmodic torticollis, is the most
common form of adult-onset focal dystonia, with estimates from
population studies ranging from 57 per million in Europe (ESDE
2000), to as high as 280 per million in the USA (Jankovic 2006).
Typically, its onset occurs in the fifth decade of life (Albanese
2013), and it affects more women than men (Defazio 2013). This
condition is characterised by abnormal movements of head, neck,
and shoulder, resulting in posturing of the head away from its nor-
mal central position (Foltz 1959). It may present predominantly
with sustained abnormal posture, spasm, jerks, tremor, or a com-
bination of these features. Neck or shoulder pain, or both, occur in
more than 70% of individuals with cervical dystonia (Chan 1991;
Tarsy 2006).
Cervical dystonia can be classified according to the dominant head
position, with the most common type involving horizontal turn-
ing, the so-called rotatory (or simple) torticollis (Albanese 2013;
Chan 1991). Other common patterns include laterocollis (tilt to
one side), retrocollis (tilt upwards resulting in neck extension)
and anterocollis (tilt downwards resulting in neck flexion). Com-
plex torticollis is a combination of these abnormal patterns, and
is found relatively infrequently in clinical practice.
The aetiology of most forms of dystonia is still not fully under-
stood, with the exception of early-onset dystonia, for which a
hereditary aetiology is common (Balint 2015). In most cases of
focal adult-onset dystonia, such as cervical dystonia, the patho-
physiology is generally considered to result from inhibition of the
central nervous system (CNS) at multiple levels (Hallett 1998),
resulting in abnormal sensorimotor integration. Cervical dystonia
can also be secondary to brain injury, infections of the CNS, drugs
(such as levodopa or antipsychotics), toxins, vascular or neoplastic
disorders, and may also be psychogenic (i.e. have a psychological
origin) (Albanese 2013). Although most cases of cervical dystonia
are currently classified as idiopathic (of unknown cause), it should
be observed that some may come to be reclassified as inherited,
since new gene discoveries are under investigation (Albanese 2013;
Balint 2015).
The natural course of cervical dystonia remains unclear. It usually
develops gradually and worsens over the initial years. The clinical
presentation in adults seldom progresses to generalised dystonia,
although it often extends to contiguous body regions. For most in-
dividuals, cervical dystonia is a life-long disorder, with only about
10% undergoing spontaneous remissions (Jahanshani 1990).
To date, no curative or disease-modifying treatments are available
for cervical dystonia.
Description of the intervention
Botulinum toxin (Bt) is a powerful biological toxin produced
by the bacterium Clostridium botulinum. The active form of bo-
tulinum toxin is a polypeptide composed of two chains: a heavy
chain (100 kDa) and a light chain (50 kDa), and by associating
with certain auxiliary proteins (haemagglutinins and non-haemag-
glutinins), the toxin forms a complex of variable size (Simpson
2004). The nontoxic proteins aid the formation of neutralising
antibodies, though beyond this their role is unclear (Frevert 2010).
Bt binds to peripheral cholinergic nerve terminals of the neuro-
muscular junction as well as sympathetic, parasympathetic and
postganglionic terminals (Simpson 2004). Bt, after binding to an
acceptor protein, is endocytosed at the presynaptic membrane of
acetylcholine nerve terminals (Pellizzari 1999). Through the ac-
tion of the N-terminal on the heavy-chain, a pore is formed on
the endocytic membrane, which permits the release of the light-
chain into the cytosol. This light chain, which is a zinc protease,
performs the key action of botulinum toxin, by cleaving soluble
N-ethylmaleimide sensitive factor attachment receptor proteins
(SNARE proteins) (Pellizzari 1999).
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SNAREs are docking proteins for acetylcholine vesicles that allow
for the release of acetylcholine into the synaptic cleft (Pellizzari
1999). As the fusion of the vesicle membranes becomes inhibited,
there is a temporary blockade of acetylcholine release at cholinergic
synapses, causing a local chemodenervation. Temporary synapses
are consequently formed via the process of axonal sprouting (
Duchen 1971; Holland 1981; Juzans 1996).
There are seven immunologically distinct botulinum toxin
serotypes (labelled A toG). These different Bt serotypes cleave spe-
cific SNARE proteins. Serotype A cleaves SNARE protein SNAP
25 located on the inner membrane, and serotype B targets synap-
tobrevin located on the vesicular membrane (Pellizzari 1999).
Botulinum toxin is injected into the muscles involved in dysto-
nia, with or without guidance by either electromyography (EMG)
or ultrasound. As a general rule, the overall dose, the number of
muscles injected and the number of injection sites per muscle are
tailored to the severity of the case and the mass of the muscle.
Within roughly three months after injection of botulinum toxin
into skeletal muscle, the nerve terminal resumes exocytosis, and
themuscle returns to its baseline clinical function, showing a wear-
ing off of response from the Bt injection (Jankovic 2004). Even-
tually, the muscle paralysis subsides, and this is associated with
the formation of new nerve sprouts capable of neurotransmission.
Over time, synaptic activity resumes in the original nerve termi-
nals, leading to sprout regression (de Paiva 1999).
Currently there are two commercially available botulinum toxin
serotypes (BtA and BtB). The following products are commonly
available (three BtA and one BtB): onabotulinumtoxinA (Botox,
Allergan Inc, Irvine, CA, USA), abobotulinumtoxinA (Dysport/
Reloxin/Azzalure, Ipsen Pharma, Boulogne Billancourt, France),
incobotulinumtoxinA (Xeomin/Bocoture Merz GmbH, Frank-
furt, Germany), and rimabotulinumtoxinB (Myobloc/Neurobloc,
Solstice Neurosciences Inc, Louisville, KY, USA). Other BtA for-
mulations are available in more restrictedmarkets and are yet to re-
ceive a generic name: Prosigne/Lantox (Lanzhou Institute of Bio-
logical Products, China), PurTox (Mentor Worldwide LLC, Santa
Barbara, CA, USA), and Neuronox (Medy-Tox Inc, South Korea)
(Walker 2014). Each type of Bt has its own relative potency and it
is estimated that 1 U of onabotulinumtoxinA roughly corresponds
to 1 U of incobotulinumtoxinA, 3 U to 5 U of abobotulinumtox-
inA, and 50 U of rimabotulinumtoxinB (Bentivoglio 2015). The
treatment cost per patient for each of the formulations is highly
variable, and depends greatly on the country and individual char-
acteristics of the people being treated, including responsiveness
to Bt and number of muscles affected. Having in mind the 2016
prices per vial for each of the formulations currently available in
the UK, and their relative potencies, 200 U of onabotulinumtox-
inA cost GBP 276, 200 U of incobotulinumtoxinA cost GBP 260,
600 U to 1000 U of abobotulinumtoxinA cost GBP 184 to GBP
308, and 10,000 U of rimabotulinumtoxinB cost GBP 198 (BNF
2016a; BNF 2016b).
How the intervention might work
The therapeutic potential of all Bt serotypes derives from their
ability to inhibit the release of acetylcholine from the presynaptic
nerve terminal into the synaptic cleft, causing local chemoden-
ervation (Jankovic 2004). In addition to this, recent research has
also suggested that Bt is active at multiple levels, namely sensory
nerve terminals, andmuscle spindles, which leads to a reduction in
sensory input and fewer muscle contractions (Filippi 1993;Matak
2014; Rosales 1996; Rosales 2010).
It has also been suggested that cortical reorganisation may result
from changes in the spinal cord, brainstem and central nervous
pathways (Palomar 2012). Animal research has shown the presence
of supra-therapeutic levels of Bt by way of retrograde axonal trans-
port and penetration of the central nervous system (Antonucci
2008; Boroff 1975). However, Bt has not been shown to penetrate
the blood-brain barrier in humans.
Until recently, SNARE proteins were considered to be the only
target-molecules of Bt. Thus, it was widely accepted that the
therapeutic and toxic actions of Bt were exclusively mediated by
SNARE cleavage preventing the release of synaptic neurotrans-
mitters. However, recent studies have suggested that a number of
Bt actions might not be mediated by SNARE cleavage, specifi-
cally regarding neuroexocytosis, cell cycle (division) and apopto-
sis (programmed cell death), neuritogenesis (formation of nerves)
and gene expression (Matak 2015). The existence of unknown Bt
molecular targets and modulation of unknown signalling path-
ways is a possibility that may prove to be relevant pharmacologi-
cally.
Why it is important to do this review
BtA is the toxin serotype that has been most intensively studied
and approved for the treatment of a large number of focal dysto-
nias. BtA is considered the first line therapy for cervical dystonia
(Albanese 2013). However, not all people with cervical dystonia
have an adequate clinical response. Primary non-response to Bt
is seen in cases where the first and subsequent treatment cycles
do not elicit a response. Cases of secondary non-response, how-
ever, respond to initial treatment, but over the course of multi-
ple treatment cycles, this effect wanes and is eventually lost. Sec-
ondary non-responsiveness is partially explained by the formation
of neutralising antibodies, though it is worth noting that there
are cases of secondary non-responders without positive antibody
titers (Hanna 1998; Lange 2009), as well as cases with positive
titers with a maintained clinical response to Bt (Brin 2008; Müller
2009). An estimated 4% to 20% of people with cervical dysto-
nia develop neutralising antibodies to the toxin (Brashear 2008;
Fabbri 2015), and if secondary non-responsiveness occurs, it is
partially related to the protein load, with a higher protein load
per dose generating higher antibody titers (Benecke 2012; Frevert
2010).
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At the present time, BtB is the only approved non-BtA formula-
tion available for the treatment of cervical dystonia in the Euro-
pean Union and North America. Both BtA and BtB have been
shown to be efficacious in comparison to placebo in the treatment
of adults with cervical dystonia (Costa 2005; Marques 2016), al-
though with apparently different safety profiles. In the context of
cervical dystonia, BtB is of particular interest as a treatment op-
tion for individuals who are non-responsive to BtA (Cullis 2000;
Eleopra 1997; Greene 1993).
Although different Bt subtypes have different molecular targets,
to date we know of no evidence from systematic reviews or ran-
domised controlled trials that presents conclusive evidence regard-
ing the comparative effectiveness of BtA and BtB for treating cer-
vical dystonia.
This is an update of a Cochrane systematic review that previously
assessed this question. The original review failed to included any
trials addressing clinical comparability of BtA versus BtB in cer-
vical dystonia. Since the release of the original review, three tri-
als have been published (Comella 2005; Pappert 2008; Tintner
2005). Furthermore, Cochrane’s criteria for evaluating studies’ risk
of bias and quality of evidence have evolved and been updated.
Therefore, the authors consider it important to update this review.
O B J E C T I V E S
To compare the efficacy, safety and tolerability of botulinum toxin
type A versus botulinum toxin type B in people with cervical
dystonia.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs), blinded, single or multiple
dose, parallel-designed, of any duration, assessing the efficacy or
safety, or both, of treatment with BtA versus BtB in adults with
cervical dystonia were eligible for inclusion in this review. If tri-
als had used inadequate randomisation or allocation concealment
methods we would have included these only in the safety analyses.
Non-parallel study designs, namely cross-over trials, were excluded
in this updated version of the review, due to uncertainty about
whether this type of study design was appropriate for studying
people with cervical dystonia, as well as methodological concerns
with regard to detection and performance bias.
Types of participants
Adults (i.e. 18 years of age and over), in any setting, with a clinical
diagnosis, made by any physician, specialist or otherwise, of idio-
pathic cervical dystonia. We included trials that enrolled partici-
pants with any form of cervical dystonia, and additional or more
widespread dystonias. Participants could have prior exposure to
BtA or BtB, and could be taking any concomitant medications, if
on stable regimens.
There were no restrictions regarding the number of participants
recruited to trials, or the number of recruitment centres.
Types of interventions
Intramuscular injections of BtA compared to BtB. We allowed
all administration schedules and injection techniques, performed
with or without guidance by either EMG or ultrasound.
Types of outcome measures
Primary outcomes
Primary efficacy outcome
Overall improvement on any validated symptomatic rating scale,
such as Tsui scale, Toronto Western Spasmodic Torticollis Rating
Scale (TWSTRS), and Cervical Dystonia Severity Scale (CDSS),
measured between weeks 3 and 6 post-injection.
Primary safety outcome
Proportion of participants with any adverse event, measured at
any point during study follow-up.
Secondary outcomes
• Change in subjective evaluation of clinical status evaluated
by both patients and clinicians, as assessed with validated
assessment tools such as the Patient Subjective Assessment of
Change, Patient Global Assessment of Improvement, Patient
Evaluation of Global Response (PEGR), Patient and Physician
Global Assessment of Change, Investigator Global Assessment of
Efficacy (IGAE), Physician Global Assessment of Change
(PGAC), and visual analogue scale (VAS) for symptom severity,
measured between weeks 3 and 6 post-injection.
• Changes in pain scores, as assessed with validated
assessment tools such as the Patient Assessment of Pain,
TWSTRS-pain sub-scale score, and VAS Pain score, measured
between weeks 2 and 6 post-injection.
• Changes in quality of life assessments, as assessed with
validated assessment tools such as the Short Form 36 (SF-36)
quality-of-life questionnaire, measured at any point during study
follow-up.
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• Numbers of participants with adverse events of special
interest, such as dysphagia, sore throat, and local injection-site
pain, measured at any point during study follow-up.
• Duration of effect, assessed by the number of days until
need for reinjection or effect waning.
Search methods for identification of studies
For this update, we expanded the search strategy to capture all the
search terms for BtA and BtB formulations that were available at
the time of the search. We designed the search strategy to include
other botulinum toxin formulations and other dystonic disorders
that were also under revision by our group.
Electronic searches
Weran the final search for the original versionof this review in June
2003, based on the search strategy developed for the Movement
Disorders Group to identify all papers from 1977, the first year
botulinum toxin was used therapeutically in any condition. The
search for the current update was run for the last time in October
2016.
For the identification of studies considered for inclusion in this
review, we developed detailed search strategies for each database
searched. Please see Appendix 1 for the CENTRAL strategy,
Appendix 2 for the MEDLINE search strategy, and Appendix 3
for the EMBASE strategy.
We assessed non-English language papers, translated them as nec-
essary and evaluated them for inclusion.
We did not search trial registries.
Databases searched
• Cochrane Movement Disorders Group trials register (June
2003);
• Cochrane Central Register of Controlled Trials
(CENTRAL; the Cochrane Library 2016, Issue 11);
• MEDLINE (1977 to 6 October 2016);
• Embase (1977 to 6 October 2016).
Searching other resources
The search strategy also included:
• searches through reference lists of located trials and review
articles concerning botulinum toxin;
• handsearch of abstracts of international congresses relevant
in the fields of movement disorders and botulinum toxins, i.e.
American Academy of Neurology, Movement Disorders Society,
International Association of Parkinsonism and Related
Disorders, and International Neurotoxin Association (1985 to
October 2016);
• personal communication with other researchers in the field;
• contact with drug manufacturers;
• whenever necessary, we contacted authors of published
trials for further information and unpublished data.
Data collection and analysis
Selection of studies
Two authors independently screened all titles and abstracts iden-
tified from searches to determine which met the inclusion criteria.
We retrieved in full text any papers identified as potentially rele-
vant by at least one author, or those without an available abstract.
Two review authors independently screened full text articles, with
discrepancies resolved by discussion and by consulting a third au-
thor where necessary to reach consensus. We collated duplicate
publications and present these by individual study. The screening
and selection process is outlined in a PRISMA flow chart (Liberati
2009), see Figure 1.
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Figure 1. BtA vs BtB in Cervical Dystonia Flow Diagram.
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Data extraction and management
Two review authors extracted data independently from included
studies using a piloted data extraction form. Any discrepan-
cies were resolved by discussion until consensus was reached, or
through consultation with a third author where necessary. The
authors extracted data on the following items from each study.
• Participants: inclusion and exclusion criteria, demographics
and clinical baseline characteristics, number and reasons for
withdrawals, exclusions and loss to follow-up, if any.
• Interventions: full description of intervention, duration of
treatment period and follow-up, providers, and co-interventions,
if any.
• Comparisons: number of participants randomised to each
arm, compliance and dropouts, reasons for dropouts, and ability
to perform an intention-to-treat analysis.
• Outcomes: definition of outcomes, use of validated
measurement tools, time point measurements, change from
baseline or post-interventional measures, and missing outcomes,
if any.
• Study design: interventional, randomised, controlled,
double-blind.
Assessment of risk of bias in included studies
We assessed the risk of bias of included studies according to the
domains described in the Cochrane tool for assessing risk of bias
(Higgins 2011b), and classified the risk of bias for each domain
as high, unclear, or low, and the overall assessment as high or
low. We assessed two further domains, which are described below:
’for-profit bias’ and ’enriched population’. We used the following
definitions for each domain in the ’Risk of bias’ assessment.
Random sequence generation
• Low risk of bias: the study performed sequence generation
using computer random number generation or a random
number table. Drawing lots, tossing a coin, shuffling cards, and
throwing dice were adequate if an independent person not
otherwise involved in the study performed them.
• Unclear risk of bias: the study authors did not report the
sequence generation method.
• High risk of bias: the sequence generation method was not
random.
Allocation concealment
• Low risk of bias: participants and investigators enrolling
participants could not foresee assignment because one of the
following, or an equivalent method, was used to conceal
allocation: central allocation, sequentially numbered drug
containers of identical appearance; sequentially numbered,
opaque, sealed envelopes.
• Unclear risk of bias: insufficient information available to
permit a judgement of ‘low risk’ or ‘high risk’.
• High risk of bias: participants or investigators enrolling
participants could possibly foresee assignments and thus
introduce selection bias.
In addition to these criteria, we considered the implications of
baseline imbalances in prognostic factors affecting the trial out-
comes, as these may lead to selection bias (Corbett 2014).
Blinding of participants and personnel
• Low risk of bias: either of the following: no blinding or
incomplete blinding, but the review authors judge that the
outcome is not likely to be influenced by lack of blinding; or
blinding of participants and key study personnel ensured, and it
is unlikely that the blinding could have been broken.
• Unclear risk of bias: any of the following: insufficient
information available to permit a judgement of ‘low risk’ or ‘high
risk’; or the trial did not address this outcome.
• High risk of bias: either of the following: no blinding or
incomplete blinding, and the outcome is likely to be influenced
by lack of blinding; or blinding of key study participants and
personnel attempted, but likely that the blinding could have
been broken, and the outcome is likely to be influenced by lack
of blinding.
Blinded outcome assessment
We considered blinding separately for different outcomes, as ap-
propriate, and, to aid in the process, divided the domain into two
categories: subjective and objective assessment.
• Low risk of bias: either of the following: no blinding of
outcome assessment, but the review authors judge that the
outcome measurement is not likely to be influenced by lack of
blinding; or blinding of outcome assessment ensured, and it is
unlikely that the blinding could have been broken.
• Unclear risk of bias: any of the following: insufficient
information available to permit a judgement of ‘low risk’ or ‘high
risk’; or the trial did not address this outcome.
• High risk of bias: either of the following: no blinding of
outcome assessment, and the outcome measurement is likely to
be influenced by lack of blinding; or blinding of outcome
assessment, but likely that the blinding could have been broken,
and the outcome measurement is likely to be influenced by lack
of blinding.
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Incomplete outcome data
• Low risk of bias: missing data were unlikely to make
treatment effects depart from plausible values. The study used
sufficient methods, such as multiple imputation, to handle
missing data.
• Unclear risk of bias: there was insufficient information
available to assess whether missing data in combination with the
method used to handle missing data were likely to induce bias to
the results.
• High risk of bias: the results were likely to be biased due to
missing data.
Selective outcome reporting
• Low risk: the trial reported the following predefined
outcomes: if the original trial protocol was available, the
outcomes reported by the trial were listed in that protocol; if the
trial protocol was obtained from a trial registry, the outcomes
reported by the trial should have been those enumerated in the
original protocol if the trial protocol was registered before or at
the time that the trial was begun.
• Unclear risk: the study authors did not report all predefined
outcomes fully, or it is unclear whether the study authors
recorded data on outcomes or not.
• High risk: the study authors did not report one or more
predefined outcomes; if the trial protocol was registered after the
trial was begun, we did not consider those outcomes to be
reliable.
For-profit bias
In order to assess the study source of funding, this domain was
added in place of the ‘other bias’ domain.
• Low risk of bias: the trial appears to be free of industry
sponsorship or other type of for-profit support that may
manipulate the trial design, conductance, or reporting of trial
results.
• Unclear risk of bias: the trial may or may not be free of for-
profit bias as the trial does not provide any information about
clinical trial support or sponsorship.
• High risk of bias: the trial is sponsored by industry or
received other type of for-profit support.
Enriched population
Because the clinical effect of botulinum toxin treatment is easily
perceived, Bt non-naive participants are likely to recognise the
presence or absence of clinical effects, or frequent adverse events,
or both, effectively revealing the respective allocation arm. It is
also relevant that, by preferentially including responders to Bt or
excluding non-responders to Bt, there is an increased likelihood
that these participants respond more favourably to Bt than a naive
population would. We opted to subdivide this domain in two:
preferential enrolment of known positive responders to Bt; and
exclusion of known poor responders to Bt.
• Low risk of bias: at least 70% of trial participants were Bt-
naive; the trial did not exclude any particular forms of cervical
dystonia.
• Unclear risk of bias: the trial did not make explicit the
percentage of participants who were known responders to Bt.
• High risk of bias: arbitrarily defined as more than 30% of
participants non-naive to Bt; explicit exclusion of people with
forms of cervical dystonia known to have a poor response to Bt,
namely people with pure anterocollis and retrocollis.
Measures of treatment effect
We compared disease symptoms at baseline to disease symptoms in
weeks 2 to 4 post-injection in the BtA and BtB arms. We extracted
continuous outcomes whenever possible. These data were then
pooled from the studies, where adequate, andused for comparison.
Dichotomous data
We based analysis of these data on the number of events and the
number of people assessed in the intervention and comparison
groups. We used these to calculate the risk ratio (RR) and 95%
confidence interval (CI).
Continuous data
We based analysis of these data on the mean, standard deviation
(SD) and number of people assessed for both the intervention and
comparison groups to calculate mean difference (MD) and 95%
CI. Where the MD was reported without individual group data,
we used this to report the study results. If more than one study
measured the same outcome using different validated tools, we cal-
culated the standardised mean difference (SMD), namely Hedges’
(adjusted) g (Hedges 1985), and 95% CI. For interpretation of
effect sizes with SMDs, we used a rule of thumb to define a small
effect (SMD = 0.2), a moderate effect (SMD = 0.5), or a large
effect (SMD= 0.8) (Cohen 1988). If necessary for comparison, we
dichotomised rating scales using each study author’s own criteria
for improvement or no improvement.
Time-to-event data
We planned to analyse these data based on log hazard ratios and
standard errors obtained from results of Cox proportional hazards
regression models. We had planned to use these in order to calcu-
late a hazard ratio (HR) and 95% CI.
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Unit of analysis issues
Whenever the included studies had multiple arms with different
dosages of one or two of the botulinum toxins, we combined all
groups to create a single pair-wise comparison, using the Review
Manager 5 (RevMan 5) calculator (RevMan 2014), according to
the methods suggested by Cochrane (Higgins 2011c). We also
would have opted to create a single pair-wise comparison in case of
multiple treatment groups using different interventions (e.g. on-
abotulinumtoxinA and abobotulinumtoxinA) if these were com-
pared to the same comparator.
This method combines all relevant experimental intervention
groups of the study into a single group, and combines all relevant
control intervention groups into a single control group. This ap-
proach avoided the duplication of the control group that would
happen if multiple comparisons (e.g. BtX dose1 versus BtY; BtX
dose2 versus BtY) were included in the meta-analysis, as well as
the loss of information if one dosage group was chosen to the
detriment of the others. If applicable, we planned to explore the
effect of dosage in subgroup analysis.
For dichotomous outcomes, both the sample sizes and the numbers
of people with events would have been summed across groups.
For continuous outcomes, means and standard deviations could
be combined using a pooled mean or SD (Higgins 2011a; Higgins
2011c).
Dealing with missing data
For missing outcome or summary data we used imputation meth-
ods to derive the missing data (where possible) and reported any
assumptions in the review. These cases were investigated, through
sensitivity analyses, to investigate the effects of any imputed data
on pooled effect estimates.
As a first option we chose to use the available information (e.g.
standard error (SE), 95%CIor exact P value) to recover themissing
data algebraically (Higgins 2011a; Higgins 2011c; Wiebe 2006).
When change from baseline SD was not reported or not possible
to extract, as was the case in Tintner 2005, we attempted to create
a correlation coefficient based on another study in this review,
and then used this correlation coefficient to impute a change from
baseline SD (Abrams 2005; Follmann 1992; Higgins 2011c).
If this were to fail, and if at least one sufficiently large and similar
study were to exist, we would use a method of single imputation
(Furukawa 2006; Higgins 2011c).
Lastly, if a sufficient number of included studies with complete
informationwere to exist, wewould have usedmultiple imputation
methods to derive missing data (Carpenter 2013; Rubin 1991).
If none of these methods were to be successful we would have
conducted a narrative synthesis for the data in question.
Assessment of heterogeneity
We assessed that studies were similar enough to allow pooling of
data using meta-analysis. Where data was pooled using meta-anal-
ysis, we assessed the degree of heterogeneity by visual inspection of
forest plots and by examining the Chi2 test for heterogeneity. We
quantified heterogeneity using the I2 statistic. We considered an I
2 value of 50% or more to represent substantial levels of hetero-
geneity, but interpreted this value in light of the size and direction
of effects and the strength of the evidence for heterogeneity, based
on the P value from the Chi2 test (Higgins 2003).
Assessment of reporting biases
We included too few studies in this review , namely fewer than
10, to allow construction of a funnel plot (Sterne 2001), and
formal testing of asymmetry (Peters 2006), which may indicate
publication bias. Should enough studies be included in future
updates of this review, we plan to undertake these analyses.
Data synthesis
We performed the analyses with RevMan 5 version 5.3 (RevMan
2014), Stata version 14 (Stata 2015) and TSA (Thorlund 2011;
TSA 2011).
Meta-analysis
We based the decision whether or not to meta-analyse data on
an assessment of whether the interventions in the included tri-
als were similar enough in terms of participants, settings, inter-
vention, comparison and outcome measures to ensure meaningful
conclusions from a statistically pooled result. We conducted data
synthesis using a random-effects model.
We pooled effect measures by applying the Mantel-Haenszel
method for dichotomous outcomes, and applying the inverse-vari-
ance or generic inverse-variancemethod for continuous outcomes.
In addition, we had planned to pool time-to-event data using
the generic inverse-variance method. We presented all results with
95% CI.
We calculated the number of participants needed to treat for an ad-
ditional beneficial outcome (NNTB) and for an additional harm-
ful outcome (NNTH) from meta-analysis estimates, rather than
treating data as if they came from a single trial, as the latter ap-
proach is more prone to bias, especially when there are signifi-
cant imbalances between groups within one or more trials in the
meta-analysis (Altman 2002). However, caution is needed in the
interpretation of these findings since they may be misleading be-
cause of variation in the event rates in each trial, differences in the
outcomes considered, and differences in clinical setting (Smeeth
1999).
Where there were no data that could be combined into a meta-
analysis we undertook a narrative approach to result synthesis.
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Trial sequential analysis
In order to explore whether the cumulative data were of adequate
power to evaluate the primary outcomes of this review, we per-
formed a trial sequential analysis (Wetterslev 2008), and calcu-
lated a required information size (also known as the heterogeneity-
adjusted required information size) (Wetterslev 2009). Trial sequen-
tial analysis aims to evaluate whether statistically significant results
of meta-analysis are reliable by accounting for the required infor-
mation size (i.e. the number of participants in the meta-analysis
required to accept or reject an intervention effect). The technique
is analogous to sequential monitoring boundaries in single trials.
Trial sequential analysis adjusts the threshold of statistical signifi-
cance and has been shown to reduce the risk of random errors due
to repetitive testing of accumulating data (Imberger 2016).
We calculated the required information size and computed the
trial sequential monitoring boundaries using theO’Brien-Fleming
approach (O’Brien1979). The required information sizewas based
on the event proportionor standard deviation in the control group;
assumption of a plausible relative risk reduction (RRR) of 10%; a
5% risk of type I error; a 20% risk of type II error (power = 80%);
and the observed heterogeneity of the meta-analysis (Jakobsen
2014; Wetterslev 2009).
Assessing the quality of the evidence
As recommended by the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) Working Group
methodology (Schünemann 2011), two reviewers independently
assessed all of the outcomes in the following domains: study lim-
itations, inconsistency, indirectness, imprecision and publication
bias. In case of disagreement the authors attempted to reach con-
sensus, consulting an independent third reviewer if necessary. For
this purpose, we used the GRADEprofiler (GRADEpro GDT)
software tool (GRADEpro GDT 2014), which we then used to
export a ’Summary of findings’ table for inclusion in the review
manuscript.
To ensure the consistency and reproducibility of GRADE judge-
ments, we applied the following criteria to each domain for all key
comparisons of the critical outcomes.
• Study limitations: we downgraded once if more than 30%
of participants were from studies classified as being at a high risk
of bias across any domain, with the exception of ’for-profit bias’.
• Inconsistency: we downgraded once if heterogeneity was
statistically significant or if the I2 value was more than 40%.
When a meta-analysis was not performed we downgraded once if
trials did not show effects in the same direction.
• Indirectness: we downgraded once if more than 50% of the
participants were outside the target group.
• Imprecision: we downgraded once if the optimal
information size criterion was not met or, alternatively, if it was
met but the 95% CI fails to exclude important benefit or
important harm (Guyatt 2011).
• Publication bias: we downgraded once where there was
direct evidence of publication bias or if estimates of effect based
on small scale, industry-sponsored studies raised a high index of
suspicion of publication bias.
We applied the following definitions to the quality of evidence
(Balshem 2011):
• high quality: we are very confident that the true effect lies
close to that of the estimate of the effect;
• moderate quality: we are moderately confident in the effect
estimate; the true effect is likely to be close to the estimate of the
effect, but there is a possibility that it is substantially different;
• low quality: our confidence in the effect estimate is limited;
the true effect may be substantially different from the estimate of
the effect;
• very low quality: we have very little confidence in the effect
estimate; the true effect is likely to be substantially different from
the estimate of effect.
’Summary of findings’ table
As has become standard practice in Cochrane Reviews, we have
included a ’Summary of findings’ table to present the main find-
ings of this review in a simple tabular format, based on the results
of the GRADE analysis. In particular, we included key informa-
tion concerning the quality of evidence, the magnitude of effect
of the interventions examined, and the sum of available data on
the outcome overall cervical dystonia improvement, proportion
of participants with adverse events, subjective change as assessed
by the patient, cervical dystonia associated pain, sore throat/dry
mouth, and dysphagia (difficulty swallowing).
Subgroup analysis and investigation of heterogeneity
Weplanned to conduct subgroup analyses according to the dosages
of Bt used, though this was not possible given the paucity of results.
In particular, we included key information concerning the quality
of evidence, themagnitude of effect of the interventions examined,
and the sum of the available data on the outcome.
R E S U L T S
Description of studies
We identified three new studies for inclusion in this update:
Comella 2005; Pappert 2008; Tintner 2005.
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Results of the search
See: Figure 1, flow diagram of study selection.
We last ran the electronic search in October 2016. The search
returned 1646 records (208 through CENTRAL; 182 though
MEDLINE; 1256 through Embase), resulting in 1599 records af-
ter removing all duplicates. After title and abstract screening, three
articles were assessed for full-text screening, with all three being
included for both the qualitative and quantitative syntheses. We
did not retrieve any unpublished trials.
Included studies
We have listed all the included studies in this review in the
’Characteristics of included studies’ table.
The three studies included in this review are parallel-group RCTs
comparingBtA andBtB for adults (i.e. 18 years of age or over) with
cervical dystonia. Trial size varied from 20 to 139 participants.
Two of the included RCTs were multi-centre studies conducted in
North America and Europe (Comella 2005; Pappert 2008), while
the remaining trial was a single-centred study conducted in the
USA (Tintner 2005). All trials were conducted in the 2000s.
Overall, 270 participants were enrolled, 171 of whom were fe-
male (63.3%). A total of 141 participants included in this review
were randomised to the BtA arm of their respective studies, with
the remaining 129 participants randomised to the BtB arm. The
average age of participants among the three trials was 53.3 years.
The baseline mean cervical dystonia symptoms were moderate to
severe in all participants, and well matched between study arms,
with baseline TWSTRS total scores of 41.8 and 45.6 for partici-
pants in Comella 2005 and Pappert 2008, respectively, which may
be interpreted as representing a moderate overall disease impair-
ment. Tintner 2005 did not provide data for baseline TWSTRS
total score. The mean duration of cervical dystonia was 7.9 years
and 6.6 years for participants in Comella 2005 and Pappert 2008,
respectively. Tintner 2005 did not provide data for the number of
years since diagnosis of dystonia. Pappert 2008 enrolled exclusively
Bt-naive participants (no prior exposure to any form of Bt), while
the remaining studies enrolled participants with a known positive
response to BtA exclusively (Comella 2005; Tintner 2005). Over-
all, 58.9% of the participants included in this review had a known
positive response to BtA. None of the included trials described the
method of participant referral and recruitment prior to study en-
rolment. Within each study, as well as when considered together,
participants were well matched for clinical and demographic char-
acteristics between BtA and BtB arms at baseline.
All studies were designed to evaluate only a single treatment ses-
sion. Two studies used doses from 100 U to 250 U of BtA - both
onabotulinumtoxinA formulations - and 5000 U to 10,000 U of
BtB (Comella 2005; Pappert 2008), while the remaining study
referred only to botulinum doses being administered at a 1:50
ratio of BtA (onabotulinumtoxinA formulation) to BtB (Tintner
2005). In all studies, and within these limits, the Bt doses admin-
istered were left at the discretion of the clinician. Techniques and
schema of Bt administration did not vary a great deal among stud-
ies. In all trials, the toxin was injected into the muscles involved
in cervical dystonia selected by the investigator, with the use of
electromyography left to the discretion of the clinician performing
the injection.
Comella 2005 and Pappert 2008 both used TWSTRS total score
at week 4 post-injection as the primary efficacy outcome. Tintner
2005 was designed with the specific objective of comparing the
autonomic effects of Bt, reporting only TWSTRS sub-scores at
baseline and at week 3 post-injection. Comella 2005 and Pappert
2008 also studied subjective response as assessed by participants
and clinicians. Regarding safety outcomes, all studies reported
treatment-associated adverse events. Comella 2005 reported data
using an intention-to-treat (ITT) principle. One study specified
the method of data analysis used (Pappert 2008), stating that data
was analysed using both per-protocol (PP) and ITT principles.
However, only PP data were reported, with the claim by the au-
thors that no difference existed between PP and ITT results. None
of the included trials had an available protocol register.
All trials were short-term, with a follow-up period lasting 16 to 20
weeks post-injection or until such time as reinjection was required.
Excluded studies
All reports that were entered for full-text screening were assessed
as eligible for inclusion in this review.
Risk of bias in included studies
See Characteristics of included studies: ’Risk of bias’ table.
The included studies were evaluated using a modified version of
the Cochrane ’Risk of bias’ tool. See Figure 2 and Figure 3 for the
’Risk of bias’ summary graphs. These assessments were based on
the information available in the primary report data.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
18Botulinum toxin type A versus botulinum toxin type B for cervical dystonia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
We considered that none of the included studies had a high risk of
bias in all domains, though we rated the ’for-profit bias’ domain
at a high risk of bias in all studies, and considered the ’selective
reporting’ domain at a high risk of bias in one study (Tintner
2005). We additionally rated all studies to as having a low risk of
bias with regard to the incomplete outcome data domain.
Allocation
Comella 2005 adequately described the method of randomisation
(permuted block allocation scheme), though made no specific de-
scription of allocation concealment. We chose to rate Comella
2005 as having a low risk of selection bias. We considered that
the remaining studies had an unclear risk of bias (Pappert 2008;
Tintner 2005), as no specific and reproducible descriptions were
made regarding themethods of randomisation and allocation con-
cealment.
Blinding
Two studies adequately reported the methods of guaranteeing
blinding, being correctly executed, double-blind controlled trials,
so we rated them as having a low risk of bias (Comella 2005;
Pappert 2008). We rated the remaining study as having an unclear
risk of bias (Tintner 2005).
Incomplete outcome data
Two studies adequately reported the number and reasons for par-
ticipant exclusions in both treatment arms (Comella 2005;Tintner
2005), these were evenly distributed across both treatment arms,
and so we rated them as having a low risk of bias. Pappert 2008
did not provide data according to an ITT principle, so we chose
to grade this study as being at an uncertain risk of attrition bias.
Selective reporting
We considered that the more clinically relevant outcomes that
are usually evaluated in intervention trials for this condition were
reported in both Comella 2005 and Pappert 2008, which is why
they were considered to be at low risk of bias for reporting data.
We rated the remaining study as having a high risk of bias for
this domain (Tintner 2005). This is because it referred in the
methods section to having selected several outcomes, though only
two of these were reported in the results. Additionally, none of the
included studies had a registered trial protocol available.
Other potential sources of bias
For-profit bias
All studies were supported, wholly or in part, by pharmaceu-
tical companies (Allergan, Inc and Soltice Neurosciences, Inc)
(Comella 2005; Pappert 2008; Tintner 2005).
Enriched population
We believe that all included studies potentially had a form of en-
riched population. Two studies exclusively enrolled positive re-
sponders to treatment with BtA (Comella 2005; Tintner 2005),
meaning that there was a potential risk of population enrichment
in 159 of the 270 participants (59%) included in this review. These
two studies also excluded people known to have poorer responses
to treatmentwith botulinum toxin (Comella 2005; Pappert 2008),
namely people with pure anterocollis and retrocollis.
Publication bias
We intended to use funnel plots to explore publication bias. How-
ever, due to the small number of included studies, the power of
this analysis was considered to be inadequate (Sterne 2011).
Effects of interventions
See: Summary of findings for the main comparison Botulinum
toxin type A versus botulinum toxin type B for adults with cervical
dystonia
The key results of this review can be found in ‘Summary of findings
for the main comparison’.
Preceding data analysis
See Dealing with missing data.
In this reviewwe derived the values of the change frombaseline SD
for each of the TWSTRS sub-scales (pain, severity and disability)
in Tintner 2005. In this case we created a correlation coefficient
for each sub-scale based on Pappert 2008, and then used this to
impute the change from baseline SD for each sub-scale, for both
BtA and BtB. Since Pappert 2008 did not report the final SD for
each intervention group we opted to substitute it with the baseline
SD, as it is reasonable to assume that the intervention does not
alter the variability of the outcome measure (Higgins 2011c). In
all cases the correlation coefficient was greater than 0.5, which
provides added security to our imputation.
We had no further need to use imputation methods.
We conducted sensitivity analyses for each case in which imputa-
tion methods were applied.
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Primary outcomes
Overall improvement on any validated symptomatic rating
scale for cervical dystonia
The Toronto Western Spasmodic Torticollis Rating Scale (TW-
STRS) is currently the most common clinical validated tool to
assess and document the status of people with cervical dystonia
(Consky 1994). The TWSTRS (total score range, 0 to 85) is com-
posite of three sub-scales that evaluate different features of cervical
dystonia, namely severity (range, 0 to 35), disability (range, 0 to
30) and pain (range, 0 to 20). The higher the score, the greater the
level ofmorbidity. In the absence of a validated value for a clinically
meaningful change in TWSTRS total score, we have considered
a 10% change from participants’ baseline status as representing a
clinically meaningful change.
Two studies (n = 231) reported data for the mean change from
baseline in TWSTRS total score (Comella 2005; Pappert 2008),
with no difference between the BtA and BtB treatment groups,
mean difference (MD) -1.44 (95% CI -3.58 to 0.70; I2 = 0%;
Analysis 1.1; Figure 4).
Figure 4. Forest plot of comparison: 1 Botulinum toxin type A versus botulinum toxin type B, outcome: 1.1
Overall cervical dystonia improvement as assessed with validated scales: change from baseline to week 4.
In relation to the trial sequential analysis, the cumulative evidence
overcame the information size generated by a conventional sample
size calculation, assuming a baseline TWSTRS of 40 points and
a required change of 10% from baseline, with an SD of 8.3. The
cumulative evidence also overcame the heterogeneity-adjusted re-
quired information size of 138 participants.
Wewere able to use data from all three included studies to calculate
the improvement on TWSTRS sub-scales, with there being no
difference between the BtA and BtB groups with regard to both
TWSTRS severity (MD -0.26; 95% CI -1.27 to 0.75; I2 = 0%;
Analysis 1.2) and TWSTRS disability (MD -0.17; 95% CI -1.19
to 0.86; I2 = 0%; Analysis 1.3).
Proportion of participants with adverse events
One study (n = 111) reported data concerning the proportion
of participants with adverse events (Pappert 2008). In this study
BtA and BtB treatment were not associated with different risks for
adverse events (RR 1.40; 95% CI 1.00 to 1.96; Analysis 1.4).
We were not able to calculate a heterogeneity-adjusted required
information size for this outcome since it was only reported in one
study. However, the total number of participants included in this
trial was less than the number generated by a conventional sam-
ple size calculation for a single adequately powered equivalence
trial. Therefore, the cumulative evidence was not adequately pow-
ered for evaluation of the proportion of participants with adverse
events.
Secondary outcomes
Change in subjective evaluation of clinical status evaluated
both by patients and clinicians
One study (138 participants) reported data with regard to sub-
jective assessments by both clinicians and patients at week 4 after
treatment. (Comella 2005) The instruments used to measure this
outcome were the Patient Global Assessment (PGA) and Subjec-
tive Global Assessment (SGA) scales. The PGA and SGA ratings
ranged from -4 (marked worsening of cervical dystonia signs) to
4 (complete abolishment of cervical dystonia signs).
Both forms of subjective assessment, measured as mean change
from baseline in PGA and SGA, were not different between BtA
and BtB groups, (PGAMD 0.20; 95% CI -0.17 to 0.57; Analysis
1.5; SGA MD 0.20; 95% CI -0.20 to 0.60; Analysis 1.6).
Pappert 2008 also mentioned having studied subjective evaluation
of clinical status by both patients and clinicians, though the final
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report did not include any data for this analysis, referring only to
the fact that all evaluations were similar between treatment arms.
Changes in pain scores, as assessed with validated
assessment tools
All included trials provided data in the form of mean change from
baseline on TWSTRS pain sub-scale (range, 0 to 20); there was
no difference between the intervention groups for this outcome
(MD -0.83; 95% CI -1.75 to 0.09; I2 = 0%; Analysis 1.7).
Changes in quality of life assessments
None of the included trials studied the effect of BtA or BtB on the
quality of life of people with cervical dystonia.
Proportion of participants with adverse events of special
interest
The most frequently reported adverse events were sore throat/dry
mouth (24.5%) (Comella 2005; Pappert 2008), and dysphagia
(18.2%) (Comella 2005; Pappert 2008; Tintner 2005).Dysphagia
was equally likely in BtA and BtB-treated participants (RR 2.89;
95% CI 0.80 to 10.41; I2=74%; Analysis 1.9). Sore throat/dry
mouth was more likely among BtB-treated participants in com-
parison to BtA-treated ones, with a RR of 4.39 (95% CI 2.43 to
7.91; I2=0%; Analysis 1.8). The NNTH in BtB-treated partic-
ipants compared to BtA-treated participants for sore throat/dry
mouth was 3 (95% CI 4 to 2).
For all other reported adverse events, including pain at injection
site, no difference was found between groups.
Duration of effect, or number of days until need for
reinjection or effect waning
This item was reported in two studies (n = 231) (Comella 2005;
Pappert 2008), though we opted not to combine the data through
a quantitative synthesis (meta-analysis) due to this outcome being
reported as survival time for the median of each arm with the
inherent limitations that entails (Michiels 2005).
Pappert 2008 reported that among its 93 participants both formu-
lations of Bt did not differ from one another - median treatment
duration of effect was 13.1 weeks in the BtA arm and 13.7 weeks
in the BtB arm (hazard ratio (HR) 0.95; 95% CI 0.56 to 1.59; log
rank P = 0.833). The trialists performed a subgroup analysis for
participants who showed an improvement from baseline at week
4 (n = 83) was also conducted, without a difference between the
groups (HR 0.79; 95% CI 0.45 to 1.41; log rank P = 0.414).
Similarly, Comella 2005 reported that among its 138 participants
both formulations of Bt did not differ from one another - me-
dian treatment duration of effect was 13.0 weeks in the BtA arm
and 11.7 weeks in the BtB arm (HR 95% CI 0.55 to 1.07). A
subgroup analysis for participants who showed an improvement
from baseline at week 4 was also conducted, with a median time
to loss of benefit of 14 weeks for BtA and 12.1 weeks for BtB. The
trialists presented the results of a log rank test for this subgroup
reporting a difference in the two distributions (HR 95% CI 0.43
to 0.98).
D I S C U S S I O N
Summary of main results
This updated review included three randomised, parallel-designed
trials, that enrolled 270 participants with cervical dystonia, of
whom 62.3% had been previously treated with botulinum toxin
type A (BtA). As can be seen in the Summary of findings for
the main comparison, BtA (onabotulinumtoxinA) and botulinum
toxin type B (BtB; rimabotulinumtoxinB) were equally effective
in reducing overall disease impairment, including disease severity,
disability, and pain. Subjective assessments by both participants
and clinicians were likewise not different between BtA and BtB.
The comparative impacts of both forms of botulinum toxin on
other domains of participants’ quality of life, such as social func-
tioning or mental health, have not been addressed in the included
trials.
Overall adverse event rates were not different between groups,
though this may be due to the small sample that was analysed
for this outcome. The short duration of the trials, as well as the
reduced sample size, precluded the drawing of strong conclusions
regarding the lack of differences between BtA and BtB. The most
common adverse events of special interest related to treatment
were sore throat/dry mouth and dysphagia. Of these, only the
risk of sore throat/dry mouth was different between the treatment
groups, with BtB-treated participants experiencing an increased
risk of this adverse event, with a number needed to treat for one
additional harmful event of 3 after a single botulinum toxin (Bt)
injection. No fatalities or serious adverse events were considered
to be related to either treatment in any of the trials. Data for
special subpopulations, such as peoplewith certain types of cervical
dystonia known to respond poorly to Bt treatment, as well as for
children and pregnant women, were not available.
We found low-to-moderate statistical heterogeneity for most effi-
cacy and safety outcome estimates, the exception being dysphagia.
Overall completeness and applicability of
evidence
All included trials addressed the primary research question directly,
using the same assessment tool, the Toronto Western Spasmodic
Torticollis Rating Scale (TWSTRS). However, data were not fully
reported for all outcomes, and in some cases results could not
be pooled and compared across studies. This limited the amount
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of data available and, consequently, our confidence in the overall
conclusions.
The participants included in the studies were not fully representa-
tive of the overall population of people with cervical dystonia. The
effects of population enrichment and the moderate overall disease
impairment (as assessed by the baseline TWSTRS scores) preclude
definite conclusions concerning all people with this condition.
Since the included trials use only onabotulinumtoxinA, there are
no data regarding the efficacy and safety profile of BtB versus other
forms of BtA, namely abobotulinumtoxinA and incobotulinum-
toxinA.
Four noteworthy factors challenge the implementation of the evi-
dence derived from this review. Firstly, a limited number of centres
conducted the research, and these were heterogeneous in terms
of their regional distribution, with all trials being conducted in
Europe or North America. Differences in clinical practice, train-
ing of experts, and local guidelines in other regions of the world
may conceivably present an obstacle to application of the evidence
summarised here. Secondly, the total number of participants across
several outcomes was less than the number of participants calcu-
lated by a standard sample size calculation for a single adequately
powered equivalence study. As such, presenting only trends in the
results, more studies are needed to provide robust evidence with
regards to these trends. Thirdly, it is common for people with cer-
vical dystonia to have concomitant medications for their condi-
tion, such as muscle relaxants and benzodiazepines. Reasonably,
in trials, participants are required to be on a stable dose of these
medications for many weeks to avoid confounding factors. As a re-
sult, little is known at present about the impact of these drug regi-
mens with regard to implementation of the evidence in this review.
Fourthly, several outcomes of interest were either poorly reported
or entirely omitted. Specifically, no quality of life assessments were
reported in any of the included studies; subjective assessments by
both participants and clinicians were not reported in two of the in-
cluded studies; the proportion of participants with adverse events
was also not reported in two of the included studies; and the time
to effect was not reported in any of the included trials, which is
of interest as this is clinically relevant for both participants and
clinicians, as well as a potentially important differentiating factor
between BtA and BtB.
Quality of the evidence
See Characteristics of included studies, ’Risk of bias’ tables, and
’Risk of bias’ summary tables (Figure 2; Figure 3).
We considered all studies to be at high risk of bias due to for-
profit bias. We additionally considered Tintner 2005 to be at a
high risk of reporting bias, since it did not report outcomes that
were collected, without providing any explanation for this omis-
sion. Additionally, we judged Tintner 2005 to be at an unclear
risk of bias for all ’Risk of bias’ domains with the exception of
attrition bias. We considered the risk of bias due to an enriched
population to be high in Comella 2005 and Tintner 2005, and
unclear in Pappert 2008. Finally, statistical heterogeneity was low
for all outcomes with the exception of the proportion of partici-
pants with sore throat/dry mouth.
Some outcomes could not be compared across studies, as some
studies lacked reporting of relevant data. Imbalances between base-
line characteristics of the participants and incomplete description
of the variables prevented confident imputation of values for miss-
ing data, which further reduced the amount of combinable data,
and therefore the precision of the results.
The included trials enrolled between 20 and 139 participants, each
individually enrolling fewer participants than the total number
that would be required for a single adequately-powered equiva-
lence trial of BtA versus BtB. Collectively however, only the fol-
lowing outcomes were under-powered: overall proportion of par-
ticipants with adverse events, change in subjective evaluation of
clinical status evaluated by patients, and changes in pain scores.
Taken together, as can be seen in Summary of findings for themain
comparison, we consider that there is low quality evidence that a
single treatment session of BtA and a single treatment session of
BtB, in certain types of cervical dystonia, are equally efficacious
in reducing disease impairment, including severity, disability, and
pain. The quality of evidence supporting the higher occurrence of
sore throat/drymouth amongBtB-treated individuals ismoderate.
There is also low-quality evidence that dysphagia occurs at the
same rate in people treated with BtA and BtB. The quality of
evidence assessing the change in subjective evaluation of clinical
status evaluated by patients is low. Regarding the overall safety and
tolerability comparison, the quality of the evidence is low,meaning
that we are unable to draw any robust conclusions. Additionally,
we can draw no conclusions regarding continued responsiveness
and long-term efficacy, which are important aspects to consider in
a chronic condition such as cervical dystonia.
Potential biases in the review process
Although we followed the methods recommended by Cochrane
in order to minimise bias in the review process, certain areas do
deserve attention. Despite having contacted experts in the area
extensively, not having searched all available clinical trial registries
opens the current review to two potential problems: firstly, the
possibility of having missed trials and also the possibility of intro-
ducing publication bias. We opted not to search trial registries as
the trials that have been conducted are well-known in the area,
and this form of search was not included in the review protocol.
An additional bias was that we could not obtain data for all out-
comes in the included trials. A further limitation of this review
is the small number of participants contributing data to each
outcome. Therefore, the results of the pooled analysis should be
viewed with caution, especially in the presence of statistical het-
erogeneity, as further studies may have an important impact in
effect size estimations.
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Agreements and disagreements with other
studies or reviews
The current review is, to our knowledge, the first systematic re-
view with data that address the question of whether one type of
botulinum toxin is superior to another or not. We have included
all randomised controlled trials that addressed this question in the
current review.
Comella 2005 reported a very large proportion of BtB-treated par-
ticipants with dysphagia and sore throat/dry mouth at week 4,
particularly when compared to the available evidence from RCTs
(dysphagia in Comella 2005: 80%; dysphagia in Marques 2016:
16%; sore throat/dry mouth in Comella 2005: 48%; sore throat/
dry mouth in Marques 2016: 17%). However, the participants
with these adverse events at baseline was likewise very high (base-
line dysphagia in Comella 2005: 14%; baseline sore throat/dry
mouth in Comella 2005: 37%), as the study exclusively enrolled
people already being treated with BtA for cervical dystonia. For
this reason, we opted to study the proportion of newly-developed
cases of each adverse event in comparison to baseline, with the
results being more in-line with both the available evidence and
clinical practice (See Table 2 for a comparison of dysphagia and
sore throat/dry mouth in Comella 2005, Marques 2016, and the
current review).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In this updated Cochrane Review we found that a single treatment
session of BtA and a single treatment session of BtB are equally
effective and well tolerated in the treatment of adults with certain
types of cervical dystonia. Treatmentwith BtB is associatedwith an
increased risk of sore throat/dry mouth when compared to treat-
ment with BtA. Overall, there is no clinical evidence to support or
not support the preferential use of one form of botulinum toxin
over another. No conclusions can be drawn regarding individuals
with predominant retrocollis or anterocollis, as these were mostly
excluded from the clinical trials.
Implications for research
We have had access only to published research data from trials of
botulinum toxin type A (BtA) versus BtB in cervical dystonia. It
is difficult to determine which and how many resources should be
invested in future research.
It would be of interest if future studies comparing BtA and BtB
were to use different formulations of BtA, namely abobotulinum-
toxinA or incobotulinumtoxinA, or both, as the trials included in
this review used only onabotulinumtoxinA.
The net benefit of both a single BtA and BtB injection in the treat-
ment of cervical dystonia has been established in the published tri-
als. Nonetheless, further studies are needed to establish the relative
effectiveness of different doses of specific botulinum toxin formu-
lations, assessing efficacy, safety, duration of effect and quality of
life across regimes. Because therapy typically requires optimising
a dose for each patient rather than administering a fixed dose of
botulinum toxin, such a line of research would be important to
support physicians’ management of doses and allow for a more
solid and safe individualisation of patient treatment. Also to be
determined is the added value, if any, of guidance methods (e.g.
electromyography) in injecting botulinum toxin into the cervical
muscles.
The time to effect of BtA and BtB were not studied in any of the
included studies, and as this may be a clinically relevant and dif-
ferentiating factor between the two formulations, future research
should endeavour to study this outcome.
Future research concerning all formulations of botulinum neuro-
toxin should endeavour to establish clinical effectiveness not only
based on changes from baseline, but also, preferably, based on
validated measures of Minimal Clinically Important Difference/
Change (Bro ek 2006). Research is required in order to establish
such a parameter for the Toronto Western Spasmodic Torticol-
lis Rating Scale (TWSTRS), currently the most widely used and
disseminated clinical scale in the field. We are, however, aware of
an effort to create a new clinical scale in dystonia - the Compre-
hensive Cervical Dystonia Rating Scale (Comella 2015), which
will include a revision of the TWSTRS, to be named TWSTRS-
2, with a Minimal Clinically Important Change validation being
planned.
It is currently uncertain whether or not the clinical effectiveness
of botulinum toxin decays over time, with repeated treatment ses-
sions, andwhether a possible loss of effectiveness occurs in all clini-
cal domains. Another related aspect is the possible development of
BtB-non-responsiveness, as there is no plausible theoretical reason
why this would not occur, as it does for BtA. Future studies com-
paring BtA and BtB should address the comparative proportion
of participants who develop clinical secondary non-responsiveness
to treatment.
Finally, in conducting this systematic reviewwewere facedwith the
fact that there is no defined core outcome set in cervical dystonia
research, as there are for other areas (Tugwell 2007). The definition
of a set of core outcomemeasures to be included in future research,
via well-established methodology to determine the inclusion of
patient-reported outcomes (Macefield 2014), would be relevant
to promote research in this field, as well as to support the clinical
effectiveness of botulinum toxin.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Comella 2005
Methods Randomised, double-blind, controlled study; randomisation in permuted block alloca-
tion schemes
Data were collected at baseline, week 4, and every 2 weeks thereafter up to 20 weeks
post-injection
Data were analysed on a ITT basis.
Participants The study was conducted in the outpatient offices of unspecified dystonia study centres
139 randomised participants
Mean age of participants was 56.7 years; 68% were female; the combined duration of
cervical dystonia was 7.9 years. The mean TWSTRS total score was 41.8
All participants had previously been exposed to a form of botulinum neurotoxin, and
were required to havemoderate severity CD, as well as aminimumof 15 on the TWSTRS
motor severity subsection, for inclusion
Exclusion criteria: predominant anterocollis and retrocollis
.
Interventions 139 participants were randomised into 2 groups: BtA group (n = 74); BtB group (n =
65)
BtA group: BtA was obtained in vials containing 100 U Clostridium botulinum toxin
type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile vacuum-
dried form without a preservative. BtA was stored at a temperature at or below -5°C and
reconstituted within 4 h of administration with 1 mL of 0.9% sterile unpreserved saline
to provide a final concentration of 100 U/mL. Subjects randomised to BtA received a
maximal dose of 250U (2.5mL). Subjects were injected with a volume of the appropriate
study drug based on previous injection amounts. Muscle selection, dosing into each
muscle, number of injection sites, and use of electromyography were at the discretion of
the injecting physician
BtB group: BtB was obtained in vials containing at least 5000 U Clostridium botulinum
toxin type B, 0.05% albumin (human), 0.01 M sodium succinate, and 0.1 M sodium
chloride buffer at a pH of 5.6. Commercially available vials of BtB contain overfill of
approximately 0.1 mL to 0.2 mL or 500 U to 1000 U BtB. The BtB was stored at a
temperature between 2°C and 8°C. Each vial of BtB was diluted with 0.25 mL of 0.9%
sterile unpreserved saline to provide a concentration of at least 4000 U/mL. Subjects
randomised to BtB received a maximal dose of 10,000 U (2.5 mL)
Outcomes Primary outcomes:
• Change in total TWSTRS score at week 4
• Duration of clinical effect (the time in days until the target TWSTRS score was
reached)
• Adverse effects evaluated by spontaneous report and adverse events interviews
Secondary outcomes:
• Physician Global Assessment of Change (-4 is very marked worsening, 0 is no
change and +4 is complete remission)
• Patient Global Assessment and pain and discomfort at baseline injection
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Comella 2005 (Continued)
No neutralising antibody testing was performed.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Random assignments were gener-
ated by the study biostatistician, were strat-
ified by center, and used permuted block al-
location schemes with blocks of randomly
allocated lengths of two or four. The study
biostatistician ensured that the initial as-
signments were balanced across centers.
The permuted block approach prevented
imbalances in the numbers randomized to
each treatment arm...”
Allocation concealment (selection bias) Low risk Quote: “Random assignments were gener-
ated by the study biostatistician, were strat-
ified by center, and used permuted block al-
location schemes with blocks of randomly
allocated lengths of two or four. The study
biostatistician ensured that the initial as-
signments were balanced across centers.
The permuted block approach prevented
imbalances in the numbers randomized to
each treatment arm...”
Blinding of participants and personnel
(performance bias)
Outcome group: Principal Investigator (PI)
Unclear risk Quote: “The principal/treating investiga-
tor (PI) enrolled the subjects, assessed
the inclusion and exclusion criteria, ob-
tained informed consent, applied and eval-
uated the UBI [unilateral brow injection],
performed the injection of study drug
(BoNTA or BoNTB), reported complica-
tions associated with injection, assessed ad-
verse events, and determined when sub-
jects reached the defined end point of the
study. (…) The PI, RI, and coordinator
were blinded to serotype administered to
each subject.”
Blinding of participants and personnel
(performance bias)
Outcome group: Rating Investigator (RI)
Low risk Quote: “The rating investigator (RI) re-
viewed the TWSTRS teaching tape to en-
sure uniform ratings and assessed subjects
using the TWSTRS (motor severity, dis-
ability, and pain) and the physician’s global
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Comella 2005 (Continued)
assessment (PGA). The RI did not perform
other study procedures. (…) The PI, RI,
and coordinator were blinded to serotype
administered to each subject.”
Blinding of participants and personnel
(performance bias)
Outcome group: Study Coordinator
Low risk Quote: “The study coordinator scheduled
study visits, recorded concomitant medica-
tions, obtained the subjective global assess-
ment (SGA), and completed study-related
questionnaires. (…) The PI, RI, and coor-
dinator were blinded to serotype adminis-
tered to each subject.”
Blinding of participants and personnel
(performance bias)
Outcome group:Independent Drug Pre-
parer
Low risk Quote: “The drug preparer obtained the
randomization code for each subject from
the study biostatistician and prepared the
BoNTA or BoNTB.”
The drug preparer was not involved in
other study procedures
Blinding of outcome assessment (detection
bias)
Outcome group: Objective Outcomes
Low risk Quote: “The PI, RI, and coordinator were
blinded to serotype administered to each
subject.”
Blinding of outcome assessment (detection
bias)
Outcome group: Subjective Outcomes
Low risk All participants had previous successful
treatment with BtA, which could have led
to the recognition of the expected effect, or
to the lack of it. However, this would pre-
sumably not have an effect as the compari-
son armwas also a botulinum toxin formu-
lation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only one post-randomisation withdrawal
occurred, in the BtA group (inability to
travel to the study site)
The ITT analysis of the primary outcome
variables for the TWSTRS and adverse
events was done for all participants exam-
ined at week 4
Selective reporting (reporting bias) Low risk The expected outcomes that are usually
evaluated in intervention trials for this con-
dition were reported in this study
For-profit bias High risk Quote: “Supported primarily by an unre-
stricted research grant from Allergan Inc.,
Irvine, CA.”
31Botulinum toxin type A versus botulinum toxin type B for cervical dystonia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comella 2005 (Continued)
Enriched population - exclusive enrolment
of positive responders
High risk Quote: “All subjects were followed up in
outpatient clinics and had previous success-
ful treatment with BoNTA, with a subjec-
tive report of at least 30% benefit.”
Quote: “At the baseline visit, the PI eval-
uated the UBI [unilateral brow injection],
and excluded subjects with UBI indicating
clinical resistance (no effacement of brow
wrinkling). Subjects were then randomized
to either BoNTA or BoNTB”
Enriched population - exclusion of poor re-
sponders
Unclear risk Quote: “Subjects were also excluded if they
had predominant anterocollis or retrocol-
lis”
Pappert 2008
Methods Randomised, double-blind, controlled trial; randomisation was done via a Interactive
Voice Response system, which created a subject randomisation number which was then
forwarded to the site pharmacist who prepared the study drug
Data were collected at baseline, week 4 post-injection and every 4 weeks until there was
a further need for botulinum therapy
Both PP and ITT analyses were performed, but the study reported only the PP analysis
Participants Multi-centre trial conducted in 24 sites in Europe (Poland, Hungary, UK, Italy, Spain,
Germany, Slovakia, France and Portugal)
111 randomised participants
Mean age = 48.9 years; 55.9% were female; and the average duration of CD was 6.6
years
Exclusion criteria: people with pure anterocollis and retrocollis, as well as previous treat-
ment with botulinum toxin
Interventions Participants were randomised into 2 groups: BtA group (n = 56); BtB group (n = 55)
BtA group: BtA was obtained by the pharmacy (100 U of vacuum-dried BtA neurotoxin
complex) and stored at or below -5°C. The final concentration of BtA was 75 U/mL.
Electromyography was used at the discretion of the investigator providing the injection
BtB group: BtB supplied by the manufacturer in insulated shipping boxes, and main-
tained at 2°C to 8°C. BtB is a clear, colourless to light yellow, sterile injectable solu-
tion containing 5000 U of BtB per mL in an isotonic solution of 0.05% human serum
albumin/0.01M succinate/0.1M sodium chloride buffer at an approximate pH of 5.6.
The final concentration of BtB was 5,000 U/mL. Electromyography was used at the
discretion of the investigator providing the injection
Outcomes Primary outcome:
• Change in total TWSTRS score at 4 weeks post-injection
Secondary outcomes:
• Change in TWSTRS sub-scores (i.e. pain, severity and disability)
• Subject pain assessment on VAS
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Pappert 2008 (Continued)
• Primary Investigator and Patient Global Assessment (5-point scales for both
frequency and intensity) on VAS at week 4
• Adverse events by spontaneous reporting and on investigation
No neutralising antibody testing was performed.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Subjects were randomized in a 1:1
ratio of BoNT-A [BtA] to BoNT-B [BtB].
The site Principal Investigator (PI) con-
tacted an Interactive Voice Response sys-
tem for a Subject Randomization Number.
”
Allocation concealment (selection bias) Low risk Quote: “Treatment allocation for the ran-
domization number was forwarded to the
site pharmacist who prepared the study
drug and had no contact with the subject
or injector. All other study personnel were
blinded.”
Blinding of participants and personnel
(performance bias)
Outcome group: Principal Investigator (PI)
Low risk Quote: “At screening (≤21 days prior to
baseline visit), the PI performed a history,
examination, and confirmed inclusion/ex-
clusion criteria. At baseline, prior to injec-
tion, the PI performed the TWSTRS (…).
At week 4 and all subsequent visits, the PI
performed the TWSTRS and Investigator
Global VAS [0 mm (much worse) to 100
mm (much better) at the time of evaluation
compared to baseline].”
Quote: “All other study personnel were
blinded”
Blinding of participants and personnel
(performance bias)
Outcome group: Rating Investigator (RI)
Low risk Quote: “At baseline, prior to injection, (…)
the AI administered the subject Pain Visual
Analogue Scale (VAS) [0 mm (worst pain
ever) to 100 mm (no pain)]
TheAdministrative Investigator conducted
the remaining visits including collection of
AEs and the administration of the Subject
Pain VAS and Subject Global VAS [rang-
ing from 0 mm (much worse) to 100 mm
(much better) at the time of evaluation
compared to baseline].”
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Pappert 2008 (Continued)
Quote: “All other study personnel were
blinded”
Blinding of participants and personnel
(performance bias)
Outcome group: Study Coordinator
Low risk Quote: “At baseline, prior to injection, (…)
the AI administered the subject Pain Visual
Analogue Scale (VAS) [0 mm (worst pain
ever) to 100 mm (no pain)]
TheAdministrative Investigator conducted
the remaining visits including collection of
AEs and the administration of the Subject
Pain VAS and Subject Global VAS [rang-
ing from 0 mm (much worse) to 100 mm
(much better) at the time of evaluation
compared to baseline].”
Quote: “All other study personnel were
blinded”
Blinding of participants and personnel
(performance bias)
Outcome group:Independent Drug Pre-
parer
Low risk Quote: “An unblinded pharmacist pre-
pared the study drug”.
Quote: “pharmacist who prepared the
study drug and had no contact with the
subject or injector”
Blinding of outcome assessment (detection
bias)
Outcome group: Objective Outcomes
Low risk Quote: “All other study personnel were
blinded.”
Blinding of outcome assessment (detection
bias)
Outcome group: Subjective Outcomes
Low risk All participants were toxin-naive.However,
this would presumably not have an effect as
the comparison arm was also a botulinum
toxin formulation
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Postrandomisation exclusionswere lowand
roughly distributed evenly between groups
(BtA group = 8; BtB group = 10)
The reasons for exclusion were presented.
Five of the exclusions in the BtB group, and
all of them (8) in theBtBgroup,were due to
;protocol violations’, which were not speci-
fied.However, the authors describe that “all
13 subjects that were excluded for protocol
violations in the PP population were from
one site where the study personnel had not
been appropriately trained.”
The data reported included only those ac-
cording to the PP principle, despite the au-
thors claiming that there were no differ-
ences between PP and ITT
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Pappert 2008 (Continued)
Selective reporting (reporting bias) Low risk The expected outcomes that are usually
evaluated in intervention trials for this con-
dition were reported in this study
For-profit bias High risk Quote: “Eric J. Pappert, MD and Terry
Germanson, PhD for The Myobloc/Neu-
robloc European Cervical Dystonia Study
Group”
Quote: “The first named author (EJP) is
an employee of SolsticeNeurosciences, Inc.
maker of MYOBLOC® (BoNT-B) and
took charge of the publication and analysis
after the studywas completed. (…)The sta-
tistical consultant (TG) is an independent
contractor paid for her analytic time by Sol-
stice Neurosciences, Inc. and has nothing
further to disclose.”
Enriched population - exclusive enrolment
of positive responders
Low risk Quote: “Exclusion criteria included: (…)
previous treatment with BoNT”
Enriched population - exclusion of poor re-
sponders
Unclear risk Quote: “Exclusion criteria included: pure
antero- or retrocollis”
Tintner 2005
Methods Randomised, double-blind, controlled trial; randomisation method not explained
Data were collected at baseline and at week 2 post-injection
It is unclear wether the data were analysed PP or by an ITT method
Participants The location of the study was not mentioned.
20 randomised participants
Mean age: BtA group = 55 years; BtB group = 64 years; 14 participants were female. The
duration of CD in the participants is unknown
Participants were required to have a previous response to BtA within the last year of
sufficient magnitude for functional improvement
Interventions BtA group: n = 11
BtB group: n = 9
No information was provided about the specific dosages or frequency of administration
of Bt therapy. No information was provided about length of follow-up
Outcomes Primary outcome:
• TWSTRS sub-score at week 2 post-injection
Secondary outcomes:
• Heart rate
• Blood pressure
• Orthostatic heart rate regulation
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Tintner 2005 (Continued)
• Heart rate variation with respiration
• Saliva production
• Ocular autonomic testing
• Composite Autonomic Scoring Scale
• Visual Functional Questionnaire
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The text refers to this trial being ran-
domised, thoughmethod of randomisation
was not specified
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not
specified.
Blinding of participants and personnel
(performance bias)
Outcome group: Principal Investigator (PI)
Unclear risk The text refers to this trial being double-
blind, though no evidence of adequate par-
ticipant blinding was provided
Blinding of participants and personnel
(performance bias)
Outcome group: Rating Investigator (RI)
Unclear risk The text refers to this trial being double-
blind, though no evidence of adequate par-
ticipant blinding was provided
Blinding of participants and personnel
(performance bias)
Outcome group: Study Coordinator
Unclear risk The text refers to this trial being double-
blind, though no evidence of adequate par-
ticipant blinding was provided
Blinding of participants and personnel
(performance bias)
Outcome group:Independent Drug Pre-
parer
Unclear risk The text refers to this trial being double-
blind, though no evidence of adequate par-
ticipant blinding was provided
Blinding of outcome assessment (detection
bias)
Outcome group: Objective Outcomes
Unclear risk The text refers to this trial being double-
blind, though no evidence of adequate in-
vestigator blinding was provided
Blinding of outcome assessment (detection
bias)
Outcome group: Subjective Outcomes
Unclear risk The text refers to this trial being double-
blind, though no evidence of adequate in-
vestigator blinding was provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “20 subjects with cervical dystonia
responsive to BTX-A were randomized and
completed the study”
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Tintner 2005 (Continued)
Selective reporting (reporting bias) High risk Although the report refers, in the meth-
ods section, to having selected several out-
comes, only 2 of these were reported in
the results. Moreover, due to inherent BtA
properties the outcome assessment usually
lasted at least until the week 16 after the
treatment section
For-profit bias High risk Trial report refers to this study having been
supported by a grant from Allergan Inc
Enriched population - exclusive enrolment
of positive responders
High risk Subjects were required to be known respon-
ders to the effects of BTA within the past
year
Enriched population - exclusion of poor re-
sponders
Low risk No reference made to exclusion of poor re-
sponders.
Abbreviations
AI: assistant investigator
AEs: adverse events
Bt: botulinum toxin
BtA: botulinum toxin type A (onabotulinumtoximA only in this systematic review)
BtB: botulinum toxin type B (rimabotulinumtoxinB)
CD: cervical dystonia
h: hour(s)
ITT: intention-to-treat analysis
PI: principal investigator
PP: per protocol
TWSTRS: Toronto Western Spasmodic Torticollis Rating Scale
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D A T A A N D A N A L Y S E S
Comparison 1. Botulinum toxin type A versus botulinum toxin type B
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall cervical dystonia
improvement as assessed with
validated scales: change from
baseline to week 4
2 231 Mean Difference (IV, Random, 95% CI) -1.44 [-3.58, 0.70]
2 Cervical dystonia associated
severity: change from baseline
to week 2-4 as assessed with
validated scales
3 251 Mean Difference (IV, Random, 95% CI) -0.26 [-1.27, 0.75]
3 Cervical dystonia associated
disability: change from baseline
to week 2-4 as assessed with
validated scales
3 251 Mean Difference (IV, Random, 95% CI) -0.17 [-1.19, 0.86]
4 Proportion of participants with
adverse events
1 111 Risk Ratio (M-H, Random, 95% CI) 1.40 [1.00, 1.96]
5 Subjective change as assessed by
the patient at week 4
1 138 Mean Difference (IV, Random, 95% CI) 0.20 [-0.17, 0.57]
6 Subjective change as assessed by
clinician at week 4
1 138 Mean Difference (IV, Random, 95% CI) 0.20 [-0.20, 0.60]
7 Cervical dystonia associated
pain: change from baseline
to week 2-4 as assessed with
validated scales
3 251 Mean Difference (IV, Random, 95% CI) -0.83 [-1.75, 0.09]
8 Adverse event: sore throat/dry
mouth
2 212 Risk Ratio (M-H, Random, 95% CI) 4.39 [2.43, 7.91]
9 Adverse event: dysphagia 3 249 Risk Ratio (M-H, Random, 95% CI) 2.89 [0.80, 10.41]
10 Adverse event: injection site
pain
1 111 Risk Ratio (M-H, Random, 95% CI) 0.14 [0.01, 2.66]
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Analysis 1.1. Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 1 Overall
cervical dystonia improvement as assessed with validated scales: change from baseline to week 4.
Review: Botulinum toxin type A versus botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type A versus botulinum toxin type B
Outcome: 1 Overall cervical dystonia improvement as assessed with validated scales: change from baseline to week 4
Study or subgroup BtA BtB
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Comella 2005 (1) 73 9.3 (8.3) 65 10.2 (8.4) 58.7 % -0.90 [ -3.69, 1.89 ]
Pappert 2008 (2) 47 8.8 (8.2268) 46 11 (8.1388) 41.3 % -2.20 [ -5.53, 1.13 ]
Total (95% CI) 120 111 100.0 % -1.44 [ -3.58, 0.70 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.34, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours BtB Favours BtA
(1) Change in total TWSTRS score at week 4. Botox 250 U; Myobloc 10000 U.
(2) Adjusted mean change in total TWSTRS score at week 4. BtA 150 U; BtB 10000 U. SE -> SD
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Analysis 1.2. Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 2 Cervical
dystonia associated severity: change from baseline to week 2-4 as assessed with validated scales.
Review: Botulinum toxin type A versus botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type A versus botulinum toxin type B
Outcome: 2 Cervical dystonia associated severity: change from baseline to week 2-4 as assessed with validated scales
Study or subgroup BtA BtB
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Comella 2005 73 3.7 (3.9) 65 3.7 (4.2) 55.3 % 0.0 [ -1.36, 1.36 ]
Pappert 2008 47 4.7 (3.8) 46 5.4 (3.9) 41.6 % -0.70 [ -2.27, 0.87 ]
Tintner 2005 11 3 (7.928) 9 2 (5.087) 3.1 % 1.00 [ -4.74, 6.74 ]
Total (95% CI) 131 120 100.0 % -0.26 [ -1.27, 0.75 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.63, df = 2 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours BtB Favours BtA
40Botulinum toxin type A versus botulinum toxin type B for cervical dystonia (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.3. Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 3 Cervical
dystonia associated disability: change from baseline to week 2-4 as assessed with validated scales.
Review: Botulinum toxin type A versus botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type A versus botulinum toxin type B
Outcome: 3 Cervical dystonia associated disability: change from baseline to week 2-4 as assessed with validated scales
Study or subgroup BtA BtB
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Comella 2005 73 2.4 (3.6) 65 2.5 (4.7) 52.8 % -0.10 [ -1.51, 1.31 ]
Pappert 2008 47 2.5 (3.9) 46 2.9 (3.7) 44.0 % -0.40 [ -1.94, 1.14 ]
Tintner 2005 11 6 (6.239) 9 4 (6.78) 3.2 % 2.00 [ -3.76, 7.76 ]
Total (95% CI) 131 120 100.0 % -0.17 [ -1.19, 0.86 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.64, df = 2 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours BtB Favours BtA
Analysis 1.4. Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 4 Proportion
of participants with adverse events.
Review: Botulinum toxin type A versus botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type A versus botulinum toxin type B
Outcome: 4 Proportion of participants with adverse events
Study or subgroup BtB BtA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Pappert 2008 37/56 26/55 100.0 % 1.40 [ 1.00, 1.96 ]
Total (95% CI) 56 55 100.0 % 1.40 [ 1.00, 1.96 ]
Total events: 37 (BtB), 26 (BtA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.95 (P = 0.051)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours BtB Favours BtA
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Analysis 1.5. Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 5 Subjective
change as assessed by the patient at week 4.
Review: Botulinum toxin type A versus botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type A versus botulinum toxin type B
Outcome: 5 Subjective change as assessed by the patient at week 4
Study or subgroup BtA BtB
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Comella 2005 73 1.6 (1.1) 65 1.4 (1.1) 100.0 % 0.20 [ -0.17, 0.57 ]
Total (95% CI) 73 65 100.0 % 0.20 [ -0.17, 0.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours BtB Favours BtA
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Analysis 1.6. Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 6 Subjective
change as assessed by clinician at week 4.
Review: Botulinum toxin type A versus botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type A versus botulinum toxin type B
Outcome: 6 Subjective change as assessed by clinician at week 4
Study or subgroup BtA BtB
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Comella 2005 73 2 (1.2) 65 1.8 (1.2) 100.0 % 0.20 [ -0.20, 0.60 ]
Total (95% CI) 73 65 100.0 % 0.20 [ -0.20, 0.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours BtB Favours BtA
Analysis 1.7. Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 7 Cervical
dystonia associated pain: change from baseline to week 2-4 as assessed with validated scales.
Review: Botulinum toxin type A versus botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type A versus botulinum toxin type B
Outcome: 7 Cervical dystonia associated pain: change from baseline to week 2-4 as assessed with validated scales
Study or subgroup BtA BtB
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Comella 2005 73 3.2 (4.5) 65 4 (4.5) 37.4 % -0.80 [ -2.30, 0.70 ]
Pappert 2008 47 1.8 (2.6) 46 2.6 (3.2) 60.1 % -0.80 [ -1.99, 0.39 ]
Tintner 2005 11 4 (5.44) 9 6 (7.53) 2.5 % -2.00 [ -7.88, 3.88 ]
Total (95% CI) 131 120 100.0 % -0.83 [ -1.75, 0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 2 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.77 (P = 0.077)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours BtB Favours BtA
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Analysis 1.8. Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 8 Adverse
event: sore throat/dry mouth.
Review: Botulinum toxin type A versus botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type A versus botulinum toxin type B
Outcome: 8 Adverse event: sore throat/dry mouth
Study or subgroup BtB BtA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Comella 2005 (1) 28/51 7/50 65.1 % 3.92 [ 1.89, 8.14 ]
Pappert 2008 22/56 4/55 34.9 % 5.40 [ 1.99, 14.66 ]
Total (95% CI) 107 105 100.0 % 4.39 [ 2.43, 7.91 ]
Total events: 50 (BtB), 11 (BtA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 4.91 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours BtB Favours BtA
(1) Cases of newly-diagnosed sore throat/dry mouth at week 4 in comparison to baseline.
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Analysis 1.9. Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 9 Adverse
event: dysphagia.
Review: Botulinum toxin type A versus botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type A versus botulinum toxin type B
Outcome: 9 Adverse event: dysphagia
Study or subgroup BtB BtA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Comella 2005 (1) 22/56 3/62 33.1 % 8.12 [ 2.57, 25.66 ]
Tintner 2005 5/9 2/11 29.6 % 3.06 [ 0.77, 12.18 ]
Pappert 2008 9/56 8/55 37.3 % 1.10 [ 0.46, 2.66 ]
Total (95% CI) 121 128 100.0 % 2.89 [ 0.80, 10.41 ]
Total events: 36 (BtB), 13 (BtA)
Heterogeneity: Tau2 = 0.95; Chi2 = 7.80, df = 2 (P = 0.02); I2 =74%
Test for overall effect: Z = 1.62 (P = 0.10)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours BtB Favours BtA
(1) Cases of newly-diagnosed dysphagia at week 4 in comparison to baseline.
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Analysis 1.10. Comparison 1 Botulinum toxin type A versus botulinum toxin type B, Outcome 10 Adverse
event: injection site pain.
Review: Botulinum toxin type A versus botulinum toxin type B for cervical dystonia
Comparison: 1 Botulinum toxin type A versus botulinum toxin type B
Outcome: 10 Adverse event: injection site pain
Study or subgroup BtB BtA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Pappert 2008 0/56 3/55 100.0 % 0.14 [ 0.01, 2.66 ]
Total (95% CI) 56 55 100.0 % 0.14 [ 0.01, 2.66 ]
Total events: 0 (BtB), 3 (BtA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours BtB Favours BtA
A D D I T I O N A L T A B L E S
Table 1. Glossary of terms
Term Definition
BtA-non-responsive People who do not experience the expected benefit from treatment with botulinum
toxin type A
Cervical dystonia or spasmodic torticollis A commonmovement disorder inwhich people have abnormalmovements or postures
of the head and neck that they cannot control. It is frequently accompanied by social
embarrassment and pain
Chemodenervation The process by which botulinum toxin causes muscular paralysis. Although all the
anatomical elements necessary for muscular control are intact (i.e. nerve, synapse and
muscle), there is a chemical process that disables the transmission of the electrical
signal from the nerve to the muscle
Dysphagia Discomfort or difficulty when swallowing
Electromyography An examination that displays the electrical activity of muscles using pieces of metal
attached to the skin or inserted into the muscle
Non-naive People who have been treated in the past with botulinum toxin
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Table 1. Glossary of terms (Continued)
Voluntary action Movements that are normally under a person’s control, that can be started and stopped
at will
Table 2. Percentage of BtB-treated participants with adverse events of special interest: Comella 2005 versus Marques 2016
versus current review
Adverse event of special inter-
est
Comella 2005 Marques 2016 Current review
Sore throat/dry mouth 48% 17% 47%
Dysphagia 80% 16% 29%
Marques 2016 is a Cochrane systematic review that studied efficacy and safety of BtB compared to placebo
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Botulinum Toxins] explode all trees
#2 Botulinum Toxins, Type A
#3 (botul* near/2 tox*):ti,ab
#4 (botox or dysport or xeomin or myobloc or rimabotulinum* or abobotuli* or onabotulinum* or oculinum or purtox or CNBTX or
Neuronox):ti,ab
#5 {or #1-#4}
#6 MeSH descriptor: [Dystonic Disorders] explode all trees
#7 MeSH descriptor: [Dystonia] explode all trees
#8 MeSH descriptor: [Torticollis] explode all trees
#9 MeSH descriptor: [Blepharospasm] explode all trees
#10 MeSH descriptor: [Meige Syndrome] explode all trees
#11 MeSH descriptor: [Hemifacial Spasm] explode all trees
#12 (cervic* near/2 dysto*):ti,ab
#13 blepharosp*:ti,ab
#14 (hem* near/2 spasm*):ti,ab
#15 (meige and (dysto* or syndrom*)):ti,ab
#16 (crani* near/2 dysto*):ti,ab
#17 (foca* near/2 dysto*):ti,ab
#18 (write* and (cramp* or dysto*)):ti,ab
#19 torticol*:ti,ab
#20 {or #6-#19}
#21 #5 and #20
#22 MeSH descriptor: [Animals] explode all trees
#23 MeSH descriptor: [Humans] explode all trees
#24 #22 not #23
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#25 #21 not #24 in Trials
Appendix 2. MEDLINE search strategy
#1 randomized controlled trial.pt.
#2 controlled clinical trial.pt.
#3 randomized.ab.
#4 placebo.ab.
#5 clinical trials as topic.sh.
#6 randomly.ab.
#7 trial.ti.
#8 1 or 2 or 3 or 4 or 5 or 6 or 7
#9 exp botulinum toxins/
#10 exp botulinum toxins, type A/
#11 (botul$ adj2 tox$).ti,ab.
#12 (botox or dysport or xeomin or myobloc or rimabotulinum$ or abobotuli$ or onabotulinum$ or oculinum or purtox or CNBTX
or Neuronox).ti,ab.
#13 9 or 10 or 11 or 12
#14 (cervic$ adj2 dysto$).ti,ab.
#15 blepharosp$.ti,ab.
#16 (hem$ adj2 spasm$).ti,ab.
#17 (meige and (dysto$ or syndrom$)).ti,ab.
#18 (crani$ adj2 dysto$).ti,ab.
#19 (foca$ adj2 dysto$).ti,ab.
#20 (write$ and (cramp$ or dysto$)).ti,ab.
#21 torticol$.ti,ab.
#22 exp dystonic disorders/
#23 exp dystonia/
#24 exp torticollis/
#25 exp blepharospasm/
#26 exp meige syndrome/
#27 exp hemifacial spasm/
#28 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27
#29 8 and 3 and 28
#30 exp animals/ not humans/
#31 29 not 30
Appendix 3. Embase search strategy
#1 random$.tw.
#2 clinical trial:.mp.
#3 placebo$.mp.
#4 double-blind$.tw.
#5 1 or 2 or 3 or 4
#6 exp Hemifacial Spasm/
#7 exp Meige Syndrome/
#8 exp blepharospasm/
#9 exp torticollis/
#10 exp Dystonia/
#11 exp Dystonic Disorders/
#12 (cervic$ adj2 dysto$).ti,ab.
#13 blepharosp$.ti,ab.
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#14 (hem$ adj2 spasm$).ti,ab.
#15 (meige and (dysto$ or syndrom$)).ti,ab.
#16 (crani$ adj2 dysto$).ti,ab.
#17 (foca$ adj2 dysto$).ti,ab.
#18 (write$ and (cramp$ or dysto$)).ti,ab.
#19 torticol$.ti,ab.
#20 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18
#21 exp Botulinum Toxins, Type A/
#22 exp Botulinum Toxins/
#23 (botul$ adj2 tox$).ti,ab.
#24 (botox or dysport or xeomin or myobloc or rimabotulinum$ or abobotuli$ or onabotulinum$ or oculinum or purtox or CNBTX
or Neuronox).ti,ab.
#25 21 or 22 or 23 or 24
#26 19 and 20 and 25
#27 limit 26 to human
WH A T ’ S N E W
Last assessed as up-to-date: 26 October 2015.
Date Event Description
6 October 2016 New search has been performed Three new trials enrolling a total of 270 participants
were included in the meta-analysis and systematic review
(Comella 2005; Pappert 2008; Tintner 2005)
9 May 2016 New citation required and conclusions have changed New authorship, accumulation of changes, reassessment
and writing according to new quality standards, addition
of a ’Summary of findings’ table
H I S T O R Y
Protocol first published: Issue 3, 2003
Review first published: Issue 1, 2005
Date Event Description
7 October 2008 Amended Converted to new review format.
5 May 2003 New citation required and conclusions have changed Substantive amendment
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D E C L A R A T I O N S O F I N T E R E S T
Costa J, Ferreira JJ, and Sampaio C were investigators in clinical trials in botulinum toxin A and B use in dystonia sponsored by Elan
(manufacturer of BtB), Allergan (manufacturer of BtA), and Ipsen (manufacturer of BtA). Searching for studies, selection of studies,
data extraction and analysis (including risk of bias), and GRADE assessment were performed by authors (FRB, GSD, MC, REM) that
are not trialists. Ferreira JJ and Sampaio C were speakers in symposiums promoted by Elan, Allergan, and Ipsen.
Moore AP has received royalties from Ipsen for the use ’LIVEchart’ scoring system for botulinum toxin treatment efficacy. He has
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S O U R C E S O F S U P P O R T
Internal sources
• Cochrane Movement Disorders Group, Portugal.
• The Walton Centre for Neurology and Neurosurgery, UK.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
For this updated review the study designs accepted were restricted to parallel-group. No changes were made in the type of participants
included or in the interventions allowed.
Adverse events, which were originally a secondary outcome, were included in this updated review as a primary safety outcome. Also,
in this safety analysis we considered the proportion of participants with the most frequent adverse events, which was not stated in the
original protocol. An assessment of the duration of effect was included as a new secondary outcome measure.
The search strategy was prolonged from the inception to October 2016.
New approaches were assumed to deal with missing data and unit of analysis issues.
The latest recommended Cochrane tool for assessing risk of bias was used in this review, which was expanded to include two additional
criteria, added by the review authors. Blinding of outcome assessment was analysed in two new subcategories: subjective and objective
assessment.
The trial sequential analysis was not in the original review protocol.
A ‘Summary of findings’ table was also added.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Botulinum Toxins [∗therapeutic use]; Botulinum Toxins, Type A [∗therapeutic use]; Neuromuscular Agents [∗therapeutic use]; Torti-
collis [∗drug therapy]
MeSH check words
Humans
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